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Abstract	
Serotonergic	contributions	to	the	anxiogenic	effects	of	cocaine	
By	
Adam	Keith	Klein	
	
Self-administration	of	cocaine	produces	an	initially	euphoric	or	“high”	state,	
following	shortly	after	by	an	aversive,	anxiogenic	“crash”.	Although	there	has	been	
extensive	research	into	the	neurobiology	of	cocaine’s	rewarding	effects,	less	
attention	has	focused	on	understanding	the	mechanisms	of	the	drug’s	aversive	
component.	Recent	research	has	identified	regions	like	the	Bed	Nucleus	of	the	Stria	
Terminalis	(BNST)	and	Lateral	Habenula	(LHb)	as	key	structures	that	contribute	to	
aversive	effects	in	humans	and	animals.	The	specific	intent	of	this	dissertation	is	to	
investigate	the	role	of	serotonin	(5-HT)	signaling	in	these	two	regions	as	it	
contributes	to	the	negative	effects	of	cocaine.	Three	main	studies	were	designed	
and	executed	to	address	this	question.	First,	to	assess	the	role	of	5-HT	perturbations	
within	the	BNST	on	the	development	of	approach-avoidance	retreat	behavior	in	
animals	trained	to	run	an	alley	for	cocaine.	Next,	the	same	methods	were	used	to	
investigate	the	role	of	5-HT	signaling	within	the	LHb,	as	animals	learned	about	
cocaine’s	negative	effects.	Finally,	the	third	study	used	selective	lesions	of	serotonin	
fibers	in	both	the	LHb	and	BNST	to	determine	a	more	precise	mechanism	of	the	
observed	serotonergic	effects.	Altogether,	the	experiments	described	in	this	thesis	
support	a	role	for	5-HT	signaling,	in	both	regions,	in	mediating	the	behavioral	
consequences	of	cocaine’s	aversive	properties.		 	
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Chapter	1.	Introduction	
	 	
	 2	
	 Cocaine	is	a	stimulant	drug	that	is	widely	used	by	humans	for	recreational	
purposes.	Per	the	National	Survey	on	Drug	Use	and	Health	(NSDUH),	nearly	one	
million	Americans	abused,	or	were	dependent	on	cocaine	in	2011.	Cocaine	and	
other	drugs	of	abuse	put	a	large	strain	on	the	economy,	with	costs	related	to	lost	
productivity,	crime	and	health	care	(ONDCP,2014).	Additionally,	cocaine	users	have	
been	shown	to	be	at	significantly	higher	risk	for	such	ailments	as	heart	attack,	
respiratory	disease,	stroke,	and	seizures	(Caplan,	Hier,	&	Banks,	1982;	Gradman,	
1988;	Lathers,	Tyau,	Spino,	&	Agarwal,	1988).	Given	the	adverse	impact	of	cocaine	
use	on	the	health	of	both	the	individual	and	the	nation,	there	has	been	considerable	
interest	in	research	aimed	at	understanding	the	factors	that	lead	to	cocaine	abuse,	
especially	the	underlying	neurobiological	mechanisms	that	motivate	cocaine	
consumption.		
1.1	Cocaine	&	Anxiety	
	 Research	into	the	effects	of	cocaine	in	humans	has	shown	that	the	drug	
produces	an	initial	sense	of	intense	pleasure,	which	is	followed	by	a	number	of	
negative	effects,	including	anxiety,	dysphoria,	irritability,	and	cravings	for	the	drug	
(Anthony,	Tien,	&	Petronis,	1989;	Resnick,	Kestenbaum,	&	Schwartz,	1977;	
Rohsenow,	Martin,	Eaton,	&	Monti,	2007;	Williamson,	Gossop,	Powis,	Griffiths,	
Fountain,	&	Strang,	1997).		Indeed,	cocaine	has	been	shown	to	exacerbate	anxiety	
seen	in	patients	suffering	from	mental	disorders	such	as	schizophrenia	(Serper,	
Alpert,	Richardson,	Dickson,	Allen,	&	Werner,	1995)	and	post-traumatic	stress	
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disorder	(Hamner,	1993),	as	well	as	to	induce	panic	attacks	(Anthony	et	al.,	1989;	
Cox,	Ron	Norton,	Swinson,	&	Endler,	1990).	These	anxiogenic	effects	are	believed	to	
drive	individuals	who	use	cocaine	to	concomitantly	consume	alcohol	(Carroll,	
Rounsaville,	&	Bryant,	1993;	Grant	&	Harford,	1990),	heroin	(Anthony	et	al.,	1989;	
Cox	et	al.,	1990;	Spotts	&	Shontz,	1984)	or	other	anxiolytic	agents	(Sheehan,	
Sheehan,	Torres,	Coppola,	&	Francis,	1991;	Williamson	et	al.,	1997)	as	a	means	of	
counteracting	the	adverse	side	effects	of	the	drug.	
	 The	anxiogenic	properties	of	cocaine	have	also	been	demonstrated	across	
numerous	animal	models	of	anxiety.	While	animals	will	reliably	self-administer	
cocaine	(Deneau,	Yanagita,	&	Seevers,	1969;	Hill	&	Powell,	1976)	and	develop	
preferences	for	environments	paired	with	the	immediate	positive	effects	of	the	drug	
(Mucha,	Van	Der	Kooy,	O’Shaughnessy,	&	Bucenieks,	1982;	Spyraki,	Fibiger,	&	
Phillips,	1982),	cocaine	administration	has	also	been	shown	to	decrease	exploration	
of	the	center	area	of	an	open	field	(Simon,	Dupuis,	&	Costentin,	1994;	Yang,	
Gorman,	Dunn,	&	Goeders,	1992),	increase	the	aversive	response	to	the	brightly	
illuminated	“light”	area	of	a	light/dark	box	(Costall,	Elizabeth	Kelly,	Naylor,	&	Onaivi,	
1989),	and	decrease	entries	into	the	open	arms	of	an	elevated	plus	maze	(Costall,	
Domeney,	Gerrard,	Horovitz,	Kelly,	Naylor,	&	Tomkins,	1990;	Paine,	Jackman,	&	
Olmstead,	2002;	Rogerio	&	Takahashi,	1992).	Cocaine	also	increases	defensive	
behaviors	in	rodents,	including;	avoidance/escape,	flight,	freezing,	threat	
vocalization,	and	defensive	attack	(for	review,	see	Blanchard	&	Blanchard,	1999).	
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Many	of	these	behaviors	are	sensitive	to	anxiolytic	drugs,	providing	further	evidence	
that	they	stem	from	an	anxiogenic	mechanism	of	cocaine	(Blanchard	&	Blanchard,	
1999;	Costall	et	al.,	1990,	1989;	Simon	et	al.,	1994).	
	 Additionally,	while	rats	will	readily	develop	a	conditioned	place	preferences	
for	environments	paired	with	the	immediate/positive	effects	of	cocaine,	they	exhibit	
conditioned	place	aversions	for	environments	paired	with	the	delayed/negative	
effects	of	the	drug	present	15	minutes	after	intravenous	injection	(Ettenberg	&	
Bernardi,	2007;	Ettenberg,	Fomenko,	Kaganovsky,	Shelton,	&	Wenzel,	2015;	
Ettenberg,	Raven,	Danluck,	&	Necessary,	1999;	Jhou,	Good,	Rowley,	Xu,	Wang,	
Burnham,	Hoffman,	Lupica,	&	Ikemoto,	2013).	Just	as	with	other	anxiety-like	
behaviors,	co-administration	of	anxiolytic	drugs	abolishes	the	development	of	
conditioned	place	aversions	to	cocaine’s	delayed/negative	effects	(Ettenberg	&	
Bernardi,	2007;	Knackstedt,	Samimi,	&	Ettenberg,	2002).	Importantly,	the	delayed	
negative	effects	produced	by	cocaine	administration	begin	while	blood	plasma	levels	
of	the	drug	are	still	quite	high	(Dyke,	Barash,	Jatlow,	&	Byck,	1976).	This	suggests	
that	the	drug’s	anxiogenic	effects	are	not	a	result	of	drug	withdrawal,	but,	rather,	of	
cocaine’s	ability	to	activate	specific	biological	processes	that	are	ultimately	
responsible	for	its	initial	positive	and	subsequent	negative	actions.	
1.2	Opponent	Process	Theory	
The	dual	and	opposing	properties	of	cocaine	align	well	with	Solomon	and	
Corbit’s	(1974)	Opponent-Process	Theory	of	Motivation.	In	their	paper,	the	authors	
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propose	that	any	stimulus	capable	of	eliciting	an	emotional	response	elicits	two	
affective	responses	that	are	temporally	dissociated	and	diametrically	opposite	in	
valence.		They	postulated,		
“First	following	the	sudden	introduction	of	either	a	pleasurable	or	aversive	
stimulus,	an	affective	or	hedonic	reaction	begins	and	quickly	rises	to	a	peak.	It	
then	slowly	declines	to	a	steady	level	where	it	remains	if	the	stimulus	quality	
and	intensity	is	maintained.	Then,	at	the	sudden	termination	of	the	stimulus,	
the	affective	reaction	quickly	disappears	and	gives	way	to	a	qualitatively	
different	type	of	affective	reaction,	which	reaches	its	own	peak	of	intensity	
and	then	slowly	disappears	with	time.”	(Solomon	&	Corbit,	1974;	pg	120).	
Solomon	and	Corbit	termed	these	the	“A”	and	“B”	processes.	Upon	stimulus	
presentation	(e.g.,	administration	of	a	drug),	the	initial	A	response	is	activated,	
increases	to	a	plateau,	and	then	decays	rapidly.	The	secondary	B	response	is	
diametrically	opposite	in	affective	valence	and	therefore	intended	to	counteract	the	
A	response	and	bring	the	organism	back	to	affective	homeostasis.	The	onset	of	the	B	
process	is	delayed	relative	to	that	of	the	initial	A	process	and	is	therefore	described	
as	being	“enslaved”	to	the	A	process	–	i.e.	without	the	activation	of	the	A	process,	
the	B	process	would	not	occur.		Accordingly,	the	net	subjective	experience	of	any	
affective	stimulus	would	be	composed	of	the	summation	of	both	A	and	B	processes,	
with	the	initial	experience	being	driven	by	A	process	(termed	the	“A	state”)	shortly	
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followed	by	experience	primarily	driven	by	the	B	process	(the	“B	state”)	(see	Figure	
1.1).		
	 In	the	case	of	cocaine	administration,	the	immediate	effects	of	the	drug	
produce	an	initial	“high”	or	euphoria	in	the	A	state,	while	the	delayed	effects	of	
cocaine	are	marked	by	an	anxiogenic,	dysphoric	B	state.		Solomon	and	Corbit	(1974)	
conceived	of	these	two	states	as	being	mediated	by	independent	neuronal	systems	
–	one	associated	with	the	initial	response	of	positive	affect	and	the	other	with	an	
opposing	negative	affect	meant	to	bring	the	organism	back	to	a	hedonic	baseline.	
They	noted,	
“…there	are	certain	systems	in	the	brain,	the	business	of	which	is	to	suppress	
or	reduce	all	excursions	from	hedonic	neutrality”	(Solomon	&	Corbit,	1974;	pg	
143)	
In	this	context,	it	seems	reasonable	to	hypothesize	that	the	decision	to	seek	
and	ultimately	self-administer	cocaine	must	take	into	account	the	dual	and	opposing	
subjective	experiences	produced	by	the	drug.	If	so,	then	a	full	understanding	of	the	
factors	that	motivate	organisms	to	ingest	cocaine	must	include	an	identification	of	
the	mechanisms	subserving	not	just	the	positive	factors	that	motivate	organisms	to	
ingest	cocaine,	but	also	its	negative	and	aversive	features.	It	is,	therefore,	the	
overarching	goal	of	the	current	dissertation	to	identify	the	underlying	
neurobiological	mechanisms	responsible	for,	or	contributing	to	the	opponent	
process	“B”	state	–	i.e.,	the	negative,	anxiogenic	effects	of	cocaine.	
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1.3	The	Runway	Model	of	Self-Administration	
	 In	order	to	better	study	these	dual	and	opposing	effects	of	cocaine,	the	
laboratory	of	Dr.	Aaron	Ettenberg	developed	a	runway	model	of	drug	self-
administration.	This	task	is	a	modification	of	a	classical	behavioral	paradigm,	
whereby	animals	are	trained	to	run	down	a	straight-arm	alleyway	and	approach	a	
goal	box	to	seek	an	incentive	stimulus	(Crespi,	1942;	Ettenberg,	2009;	Hull,	1932,	
1934a,	1934b).	In	these	studies,	the	latency	to	leave	the	start	box	and	the	time	
required	for	the	animal	to	enter	the	goal	box	serve	as	measures	of	the	strength	of	
approach	behaviors.	Thus,	the	animal	must	perform	an	operant	behavior	(i.e.,	run	
the	length	of	the	alley)	in	order	to	return	to	an	environment	that	had	previously	
been	paired	with	drug	administration.	In	this	way	the	paradigm	includes	aspects	of	
both	an	operant	self-administration	task	(running	for	the	drug	reinforcer)	and	a	
conditioned	place	preference	test	(the	development	of	drug-goal	box	associations).	
The	behavior	of	subjects	running	in	an	alleyway	may	be	best	explained	by	
Miller’s	(1959)	Theory	of	Conflict.	According	to	this	theory,	an	incentive	stimulus	
(i.e.,	one	possessing	motivational	impact)	may	either	produce	behavioral	approach,	
avoidance,	or	a	mixed	approach/avoidance	gradient	dependent	on	the	inherent	or	
conditioned	attributes	of	the	goal	stimulus.	
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Figure	1.1.	Schematic	diagram	of	Solomon	&	Corbit’s	“Opponent	Process	Theory	of	
Motivation.”	The	bottom	curve	illustrates	the	opponent	“A”	and	“B”	processes.	
While	the	A	process	begins	immediately	following	stimulus	onset,	quickly	reaches	an	
asymptote	and	then	rapidly	decays,	the	B	process	begins	shortly	after	and	in	
response	to	the	A	process,	and	decays	more	gradually,	and	remains	in	effect	for	a	
short	time	even	after	the	stimulus	is	removed.	The	top	curve	illustrates	the	
subjective	experience	of	the	organism	produced	by	the	stimulus	–	effectively	a	
summation	of	both	the	A	and	B	processes.	As	shown,	immediately	following	stimulus	
onset	an	organism’s	experience	is	that	of	the	A	state,	which	is	above	baseline	on	the	
ordinate	hedonic	scale.	Following	stimulus	termination,	the	organism’s	experience	
shifts	to	that	of	the	B	state	–	below	baseline	on	the	ordinate	hedonic	scale.		 	
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Miller	postulated	that	if	a	stimulus	is	purely	positive	in	nature,	then	the	
subjects’	motivation	to	approach	that	stimulus	will	increase	in	strength	as	the	
subject	nears	the	stimulus	(an	approach	gradient).	Likewise,	for	a	stimulus	that	is	
perceived	as	purely	negative	in	valence,	the	subjects’	motivation	to	avoid	that	
stimulus	will	grow	with	increasing	proximity	to	that	stimulus	(an	avoidance	
gradient).	However,	the	increases	in	strength	for	approach	and	avoidance	gradients	
are	not	equal.	The	asymptote	for	approach	behavior	towards	a	positive	stimulus	has	
been	shown	to	occur	at	greater	distances	than	that	for	the	avoidance	of	a	negative	
stimulus	(Smith,	1960).		Thus,	when	a	stimulus	possesses	both	positive	and	negative	
qualities	(i.e.	mixed	properties),	the	animal	will	first	initiate	approach	behavior,	but,	
as	it	nears	the	stimulus,	avoidance	motivation	increases	and	may	eventually	halt	the	
forward	approach	altogether.	The	competition	between	these	two	gradients	results	
in	an	approach-avoidance	oscillatory	behavior	where	animals	will	first	progress	
toward,	and	then	withdraw	away	from,	the	goal	box	(Geist	&	Ettenberg,	1997;	
Miller,	1944).	Geist	and	Ettenberg	(1997)	labeled	this	back-and-forth	response	as	
“retreat”	behavior,	which	develops	in	runway	procedures	using	a	goal	box	that	is	
associated	with	a	dual	positive	and	a	negative	incentive	stimulus,	such	as	food	+	foot	
shock,	or	water	+	foot	shock	(Cohen,	Young,	Velazquez,	Groysman,	Noorbehesht,	
Ben-Shahar,	&	Ettenberg,	2009;	Geist	&	Ettenberg,	1997;	Martin	&	Ross,	1964;	
Miller,	1944).	While	the	approach-avoidance	retreat	behavior	may	persist	for	some	
time,	as	long	as	the	positive	associations	of	the	goal	box	are	greater	than	the	
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negative	associations,	the	animal	will	eventually	choose	to	enter	the	goal	box	to	
retrieve	the	mixed	incentive	stimulus.		
In	our	laboratory,	this	runway	model	has	been	adapted	to	examine	drug	self-
administration.	Here,	animals	traverse	a	straight	alley	once	per	day	to	enter	a	goal	
box	where	they	receive	a	single	intravenous	(i.v.)	injection	of	a	drug	reinforcer	
(Ettenberg,	2009;	Geist	&	Ettenberg,	1990).	Early	on,	it	was	noticed	that	rats	trained	
to	run	for	an	i.v.	injection	of	cocaine	developed	a	unique	pattern	of	responding	that	
was	not	observed	with	other	drug	reinforcers	(Ettenberg	&	Geist,	1993;	Guzman	&	
Ettenberg,	2004;	Su,	Wenzel,	Baird,	&	Ettenberg,	2011).	Cocaine-reinforced	animals	
exhibited	decreased	start	latencies	(i.e.	they	leave	the	start	box	more	and	more	
quickly)	over	trials,	demonstrating	an	increasing	motivation	to	seek	the	drug	and	
approach	the	goal.	However,	as	the	subjects	experienced	more	trials	(and	gained	
more	experience	with	the	dual	consequences	of	the	drug),	they	began	to	exhibit	
progressively	longer	run	times	(it	took	them	longer	and	longer	to	actually	enter	the	
goal	box).	This	increase	in	run	times	was	found	to	be	a	direct	result	of	the	increasing	
occurrence	of	the	approach-avoidance	“retreat”	behaviors	wherein	rats	rapidly	
approached	the	goal,	but	then	stopped	at	the	entry	threshold,	turned,	and	ran	back	
towards	the	start	box	(Ettenberg	&	Geist,	1991).	These	retreats	reflect	the	inherent	
conflict	about	goal	box	entry	stemming	from	the	mixed	positive	(reinforcing)	and	
negative	(anxiogenic)	effects	of	cocaine	administration	that	both	eventually	become	
associated	with	the	goal	box	(for	review,	see	Ettenberg,	2004),	and	can	be	mitigated	
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by	pretreatment	with	various	anxiolytic	compounds	(Ettenberg	&	Bernardi,	2006;	
Ettenberg	&	Geist,	1991;	Guzman	&	Ettenberg,	2004;	Knackstedt	&	Ettenberg,	2005).	
Consistent	with	Miller’s	Theory	of	Conflict	(1944,	1959),	the	turning	point	in	the	alley	
where	the	animal	stops	and	retreats	away	from	the	goal	box	is	most	frequently	
observed	at	the	goal	box	threshold	where	the	anxiety	gradient	is	at	its	peak	
(Ettenberg	&	Geist,	1991;	for	review,	see	Ettenberg,	2009).	Thus,	the	runway	self-
administration	model	provides	a	unique	means	of	investigating	both	the	positive	
and	negative	properties	of	cocaine	within	the	same	animal	on	the	same	trial.		
The	runway	model	has	several	additional	strengths.	Since	cocaine	is	only	
administered	at	the	termination	of	each	trial	and	animals	are	tested	only	once	per	
day,	the	protocol	allows	for	the	assessment	of	the	subject’s	motivation	to	seek	
cocaine	prior	to	drug	delivery.	This	permits	testing	to	be	completely	free	from	any	
direct	confounding	side	effects	of	the	drug	reinforcer	itself—e.g.	sedative	or	
stimulant	motoric	influences.	The	runway	therefore	serves	as	an	excellent	tool	to	
distinguish	between	the	motivation	to	seek	cocaine	and	the	reinforcing	
consequences	of	cocaine	delivery.		For	example,	in	one	study	by	Ettenberg	and	
McFarland	(2002),	rats	trained	to	run	an	alleyway	for	heroin	reinforcement	showed	
no	changes	in	run	times	when	pretreated	with	a	dopamine	(DA)	or	opioid	antagonist	
drug,	indicating	a	preserved	motivation	to	reach	the	goal.	However,	once	the	animal	
reached	the	goal	box	and	ingested	the	heroin	under	the	influence	of	the	antagonist	
treatment,	the	reinforcing	properties	of	heroin	were	diminished.	This	was	evidenced	
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by	a	significant	reduction	in	subjects’	motivation	to	approach	the	goal	on	the	
following	day	(Ettenberg	&	McFarland,	2002).	
The	ability	to	test	operant	behavior	in	an	un-drugged	state	is	a	key	difference	
between	the	runway	model	and	traditional	drug	self-administration	models.	In	
typical	operant	box	procedures,	the	initial	drug	injection	will	typically	be	followed	by	
subsequent	responding	by	the	subject	in	order	to	obtain	more	drug.	This	behavior	
represents	the	motivation	of	an	already	drugged	animal	to	maintain	their	desired	
level	of	intoxication.	The	distinction	between	motivated	behavior	in	a	drugged	vs.	
un-drugged	state	is	critical	when	investigating	the	dual	properties	of	cocaine.	Due	to	
the	bi-phasic	effects	of	cocaine,	all	additional	operant	behavior	after	the	initial	
infusion	may	in	fact	be	motivated	by	the	dual	desire	of	the	animal	to	experience	
cocaine’s	positive	effects	while	also	alleviating	the	onset	of	the	drug’s	negative	
effects.	Thus,	subjects	are	likely	not	only	responding	for	the	positive	effects	of	
cocaine,	but	also	for	the	negative	reinforcing	effects	of	the	drug.	This	results	in	an	
inability	to	clearly	distinguish	between	the	positive	and	negative	motivational	
influences	in	the	traditional	operant	behavioral	task.	In	contrast,	the	dissociation	of	
the	positive	(start	time)	and	negative	(retreats)	motivational	components	of	drug	
seeking	is	relatively	simple	when	utilizing	a	runway	model	of	self-administration.		
Of	course,	like	all	behavioral	tests,	the	self-administration	runway	has	its	
inherent	weaknesses.	The	principal	among	these	is	the	fact	that,	like	the	conditioned	
place	test,	the	runway	model	of	self-administration	does	not	mimic	the	patterns	of	
	 13	
drug	use	typically	seen	in	humans.	While	the	fact	that	this	protocol	requires	only	a	
single	injection	of	drug	per	day	allows	for	motivational	testing	to	occur	in	the	un-
drugged	state,	it	arguably	does	not	model	human	drug	use	nor,	therefore,	meet	the	
DSM-V	criterion	for	substance	abuse	or	dependence	(American	Psychiatric	
Association,	2013).	Thus,	if	the	primary	goal	of	a	research	program	is	to	model	
“addiction”,	the	runway	model	may	not	be	the	ideal	behavioral	task.	One	could,	of	
course,	first	render	the	animal	subjects	“addicted”	through	the	utilization	of	an	
alternative	paradigm	and	then	assess	motivation	to	obtain	the	drug	in	the	runway;	a	
technique	which	has	successfully	been	employed	in	our	laboratory	(Ben-Shahar,	
Posthumus,	Waldroup,	&	Ettenberg,	2008).	Lastly,	the	runway	model	places	
significant	physical	demands	on	the	animals.	In	this	test,	rats	are	required	to	
traverse	an	alleyway	approximately	six	feet	long	to	obtain	the	reinforcer,	and	the	
dependent	variables	measured	are	contingent	upon	the	movement	of	the	animal.	
Consequently,	any	manipulations	that	may	alter	locomotor	ability	or	propensity	to	
respond	(e.g.	systemic	DA	antagonist	pretreatment)	may	compromise	the	
interpretation	of	the	runway	measures.	It	is	therefore	necessary	to	assess	the	
locomotor	capacity	of	the	subjects	in	interpreting	the	effects	of	chronic	treatments	
(e.g.	lesions)	or	pretreatments	that	may	affect	runway	behavior.		
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1.4	Brain	Systems	Implicated	in	Anxiety	
1.4.1	The	Bed	Nucleus	of	the	Stria	Terminalis	(BNST)	
As	described	above,	cocaine	produces	a	variety	of	psychological	and	
physiological	effects	that	can	induce	a	state	of	anxiety	in	both	humans	and	animals.	
There	are	a	few	brain	regions	that	appear	well	positioned	to	mediate	and	regulate	
the	generation	of	cocaine-induced	anxiety.	One	of	these	structures,	located	in	what	
is	now	known	as	the	“extended	amygdala”,	was	first	described	by	Johnston	in	1923,	
when	he	noted	that	the	"bed	of	the	stria	terminalis"	forms	a	continuous	forebrain	
structure,	which	includes	both	the	centromedial	portion	of	the	amygdala	as	well	as	
the	adjoining	nucleus	accumbens	(NAcc)	(Johnston,	1923)	(See	Fig.	1.2	below).	
Nearly	half	a	century	later,	work	by	Heimer	and	colleagues	advanced	the	concept	of	
the	extended	amygdala	as	an	anatomically	and	functionally	interconnected	system	
within	the	basal	forebrain	comprised	of	the	bed	nucleus	of	the	stria	terminalis	
(BNST),	central	nucleus	of	the	amygdala	(CeA),	and	a	portion	of	the	NAcc	shell	
(Alheid	&	Heimer,	1988;	Olmos	&	Heimer,	1999).		This	macrostructure	receives	its	
primary	input	from	non-isocortical	regions	of	the	limbic	system	and	sends	prominent	
projections	to	autonomic	and	somatomotor	centers	of	the	lateral	hypothalamus	and	
brain	stem	as	well	as	to	the	VTA	and	endocrine	nuclei	of	the	medial		 	
	 15	
	
	
	
	
	
Figure	1.2.	Schematic	diagram	of	brain	circuits	involved	with	the	positive	and	
negative	actions	of	cocaine.	Major	serotonergic	pathways,	emanating	from	the	
Dorsal	Raphé	Nucleus,	that	are	investigated	by	this	dissertation	are	highlighted	in	
red.	These	pathways	project	to	key	regions	that	are	strongly	associated	with	stress,	
anxiety,	and	negative	outcomes.	The	two	under	consideration	by	this	work	are	the	
Bed	Nucleus	of	the	Stria	Terminalis	(BNST),	or	“Extended	Amygdala”,	in	blue,	and	the	
Lateral	Habenula	(LHb)	in	green.	 	
	 16	
hypothalamus	(Dong	&	Swanson,	2004;	Heimer,	2003).	Its	position	at	the	interface	
between	limbic	and	autonomic,	as	well	as	the	brain’s	motor	systems,	places	the	
extended	amygdala	at	an	ideal	neuroanatomical	location	to	work	as	an	integrator	
between	incoming	affective	stimuli	and	their	corresponding	physiological	and	
behavioral	responses	(Mogenson,	Jones,	&	Yim,	1980).	Indeed,	much	research	has	
implicated	the	extended	amygdala	in	the	processing	of	stress-related	stimuli	and	
activation	of	the	hypothalamic-pituitary-adrenal	(HPA)	axis	(Herman,	Figueiredo,	
Mueller,	Ulrich-Lai,	Ostrander,	Choi,	&	Cullinan,	2003;	Ulrich-Lai	&	Herman,	2009).			
Within	the	extended	amygdala,	both	the	BNST	and	CeA	have	been	shown	to	
play	a	critical	role	in	the	experience	of	fear	and	anxiety	states	(Davis,	2006;	
Schweimer,	Fendt,	&	Schnitzler,	2005).	Fear	is	typically	defined	as	a	transient	
adaptive	state	of	apprehension	to	an	immediate	threat,	whereas	anxiety	is	
considered	a	future-oriented	sustained	mood	state	associated	with	potential	threat	
(Davis,	Walker,	Miles,	&	Grillon,	2010).	Historically,	the	CeA	has	been	implicated	in	
the	production	of	fear	states	while	activation	of	the	BNST	has	been	associated	with	
anxiety.	In	support	of	this	model,	lesions	of	the	CeA,	but	not	the	BNST,	block	fear-
potentiated	startle	to	a	light	cue	previously	paired	with	footshock	(Hitchcock	&	
Davis,	1986,	1991).	Conversely,	light-enhanced	startle	(a	paradigm	that	exploits	the	
unconditioned	anxiogenic	effects	of	bright	light	exposure	in	rodents)	is	blocked	by	
infusion	of	the	a-amino-3-hydroxy-5-methyl-4-isoxazole-propionate	(AMPA)	
receptor	antagonist	NBQX	into	the	BNST,	but	is	not	blocked	when	the	same	drug	is	
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delivered	to	the	CeA	(Walker	&	Davis,	1997).	These	results	are	likely	due	to	a	
differential	involvement	in	short-duration	versus	sustained	longer-duration	fear	
responses	between	the	CeA	and	BNST,	respectively,	rather	than	differences	in	the	
processing	of	conditioned	versus	unconditioned	stimuli.	To	support	this	conclusion,	
Davis	and	colleagues	(1989)	utilized	a	conditioned	fear	paradigm	in	which	seven	
randomly	presented	footshocks	were	delivered	during	a	long-lasting	(eight	minute)	
auditory	stimulus.	Rats	learned	that	during	conditioned	stimulus	presentation	they	
are	at	risk	for	shock,	but	they	did	not	know	exactly	when	that	shock	might	occur.	
Following	conditioning,	intra-BNST	AMPA	antagonism	decreased	fear-potentiated	
startle	later	in	the	stimulus	presentation	(minutes	5–8)	but	not	at	the	start	of	the	
conditioned	stimulus	(minutes	1–4)(Davis,	Schlesinger,	&	Sorenson,	1989).	This	
supports	the	notion	that,	although	the	CeA	is	involved	in	shorter	duration	fear	
states,	the	BNST	plays	a	role	in	sustained	fear,	which	may	be	better	described	as	
anxiety.	What	is	clear,	is	that	both	regions	of	the	extended	amygdala	play	an	
important	role	in	the	physiological	processing	of	stressful	stimuli.	
Aside	from	fear	and	anxiety	states	generated	by	external	stimuli,	both	the	
CeA	and	the	BNST	have	also	been	implicated	in	negative	affective	states	resulting	
from	drug	withdrawal.		Similar	to	the	withdrawal-related	dysphoria	observed	in	
human	addicts	(Gawin,	1986),	animals	exhibit	heightened	anxiety	following	
cessation	of	repeated	daily	cocaine	administration.	In	the	first	24-48	hours	following	
cocaine	abstinence	(after	a	period	of	chronic	drug	exposure),	increased	stress	
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responsivity	can	be	observed	in	rodents	as	measured	by	an	increase	in	the	
propensity	to	defensively	bury	a	probe	previously	associated	with	footshock	(Basso,	
Spina,	Rivier,	Vale,	&	Koob,	1999;	Harris	&	Aston-Jones,	1993)	or	to	avoid	open	
spaces	in	an	elevated	plus	maze	(DeVries	&	Pert,	1998;	Perrine,	Sheikh,	
Nwaneshiudu,	Schroeder,	&	Unterwald,	2008;	Rudoy	&	Van	Bockstaele,	2007;	
Sarnyai,	Bíró,	Gardi,	Vecsernyés,	Julesz,	&	Telegdy,	1995).	Increased	reactivity	in	
these	models	is	indeed	correlated	with	activation	of	both	the	CeA	and	BNST	(Gracy,	
2001;	Hamlin,	Buller,	Day,	&	Osborne,	2004;	Jin,	Araki,	Nagata,	Suemaru,	Shibata,	
Kawasaki,	Hamamura,	&	Gomita,	2003);	moreover,	antagonism	of	either	area	
reduces	withdrawal-enhanced	anxiety	behavior	in	these	paradigms	(Harris	&	Aston-
Jones,	1993;	Rudoy	&	Van	Bockstaele,	2007;	Sahuque,	Kullberg,	Mcgeehan,	Kinder,	
Hicks,	Blanton,	Janak,	&	Olive,	2006).		
In	extended	drug	withdrawal	(following	48	hours	abstinence),	animals	
continue	to	exhibit	heightened	responsivity	to	stressors,	however,	this	appears	to	be	
the	case	only	under	conditions	in	which	anxiety	is	activated	by	presentation	of	an	
aversive	stimulus	(e.g.,	the	defensive	burying	paradigm)	and	not	in	situations	where	
discrete	stress-predictive	stimuli	are	lacking	(e.g.,	the	elevated	plus	maze)	(Erb,	
Kayyali,	&	Romero,	2006).	Augmented	stress	reactivity	may	play	a	role	in	the	
increased	likelihood	for	aversive	stimuli	to	reinstate	drug-seeking	behavior	following	
extended	withdrawal	(Shaham,	Shalev,	Lu,	de	Wit,	&	Stewart,	2003).		In	accordance	
with	this	idea,	Sorge	and	Stewart	(2005)	found	that	in	rats	with	a	history	of	chronic	
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extended	cocaine	access,	the	ability	of	footshock	stress	to	reinstate	responding	on	a	
lever	previously	associated	with	cocaine	delivery	increased	during	progressive	
abstinence	and	remained	robust	after	60	days	of	withdrawal	(Sorge	&	Stewart,	
2005).	Additionally,	similar	to	what	is	seen	during	extended	withdrawal,	the	
extended	amygdala	has	been	implicated	in	stress-induced	reinstatement	of	cocaine	
seeking	(for	review,	see	Erb,	Shaham,	&	Stewart,	2001).		Prior	research	from	our	
own	laboratory	has	highlighted	the	role	of	NE	signaling	within	the	extended	
amygdala	as	it	relates	to	the	anxiogenic	effects	of	cocaine	(Wenzel,	Cotten,	
Dominguez,	Lane,	Shelton,	Su,	&	Ettenberg,	2014;	Wenzel,	Waldroup,	Haber,	Su,	
Ben-Shahar,	&	Ettenberg,	2011).	
Because	of	the	strong	link	between	the	extended	amygdala	and	the	
production	of	anxiety-like	behaviors,	the	BNST	was	selected	for	this	dissertation	as	
one	of	the	prime	candidates	for	investigation	into	its	role	in	mediating	the	
anxiogenic	effects	of	cocaine.		
1.4.2.	The	Lateral	Habenula	
In	recent	years,	another	structure	has	come	into	focus	in	relation	to	the	
aversive	actions	of	cocaine.	The	lateral	habenula	(LHb)	is	an	epithalamic	structure	
composed	mainly	of	glutamatergic	cell	bodies	that	is	highly	conserved	across	
vertebral	species	(Aizawa,	Kobayashi,	Tanaka,	Fukai,	&	Okamoto,	2012;	Lammel,	Lim,	
Ran,	Huang,	Betley,	Tye,	Deisseroth,	&	Malenka,	2012;	Li,	Piriz,	Mirrione,	Chung,	
Proulx,	Schulz,	Henn,	&	Malinow,	2011;	Stamatakis	&	Stuber,	2012;	Stephenson-
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Jones,	Floros,	Robertson,	&	Grillner,	2012;	Sutherland,	1982).	The	LHb	receives	
significant	input	from	a	wide	variety	of	brain	structures,	including	the	globus	
pallidus,	the	lateral	hypothalamus,	hippocampus,	prefrontal	cortex,	and	the	ventral	
pallidum	via	the	stria	medullaris	(Herkenham	&	Nauta,	1977;	Hong	&	Hikosaka,	
2008;	Velasquez,	Molfese,	&	Salas,	2014).	The	LHb	in	turn	projects	through	the	
fasciculus	retroflexus	to	areas	including	the	dorsal	and	median	raphé	nuclei,	
hypothalamus,	locus	coeruleus,	and	dorsal	pontine	central	gray	(Aghajanian	&	
Wang,	1977;	Araki,	McGeer,	&	McGeer,	1984;	Herkenham	&	Nauta,	1979;	Hikosaka,	
Sesack,	Lecourtier,	&	Shepard,	2008;	Quina,	Tempest,	Ng,	Harris,	Ferguson,	Jhou,	&	
Turner,	2015;	Sutherland,	1982).	Although,	many	LHb	connections	may	in	fact	be	
mediated	though	the	rostromedial	tegmental	nucleus	(RMTg)	to	which	the	LHb	
sends	a	significant	projection	(Hikosaka,	2010;	Jhou,	Geisler,	Marinelli,	Degarmo,	&	
Zahm,	2009).	According	to	Baker,	Oh,	Kidder,	and	Mizumori	(2015),	the	afferent	and	
efferent	projections	of	the	LHb	give	us	significant	insight	into	the	role	of	the	LHb.	
These	investigators	hypothesize	that	the	LHb	plays	a	vital	role	in	behavioral	
flexibility,	where	it	serves	as	a	connection	between	the	internal/external	states	of	
the	organism	and	the	midbrain	areas	subserving	motivation	and	learning.	In	other	
words,	Baker	and	colleagues	(2015)	suggest	that	the	LHb	takes	in	information	about	
the	current	state	of	the	organism,	and	passes	that	information	along	with	the	goal	of	
altering	behavior	to	gain	rewards	and	avoid	punishments	(Baker,	Oh,	Kidder,	&	
Mizumori,	2015).	Indeed,	with	its	projections	to	the	dorsal	and	median	raphé	nuclei,	
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the	locus	coeruleus,	and	RMTg,	the	LHb	is	located	in	an	ideal	position	to	regulate	
and	coordinate	the	release	of	all	the	major	monoamine	neurotransmitters	(DA,	5-
HT,	and	NE)	throughout	the	brain	(See	Fig	1.2).		
Disruption	of	the	LHb	might	therefore	be	expected	to	impair	an	organism’s	
ability	to	effectively	and	efficiently	alter	its	behavior	to	changing	circumstances.	
Evidence	for	this	type	of	disruption	was	shown	in	studies	wherein	rats	with	
excitotoxic	lesions	of	the	LHb	were	unable	to	learn,	maintain	or	switch	behaviors	in	
response	to	changing	contingencies	regarding	appetitive	rewards	(Christoph,	
Leonzio,	&	Wilcox,	1986;	Thornton	&	Davies,	1991;	Thornton	&	Evans,	1984).		
If	the	hypothesis	put	forth	by	Baker	et	al.	(2015)	regarding	the	role	of	the	LHb	
in	behavioral	flexibility	is	indeed	correct,	then	one	would	predict	that	the	LHb	should	
be	particularly	sensitive	to	aversive	or	harmful	stimuli,	as	these	outcomes	require	
significant	changes	in	behavior.	In	accordance	with	this	view,	it	has	been	noted	that	
not	only	do	multiple	afferents	projecting	to	the	LHb	come	from	sources	known	to	be	
associated	with	anxiety,	but	also	that	the	LHb	has	been	implicated	in	mediating	the	
effects	of	anxiety,	stress,	and	avoidance	learning	(Amat,	Sparks,	Matus-Amat,	Griggs,	
Watkins,	&	Maier,	2001;	Caldecott-Hazard,	Mazziotta,	&	Phelps,	1988;	Gao,	
Hoffman,	&	Benabid,	1996;	Gottesfeld,	1983;	Murphy,	DiCamillo,	Haun,	&	Murray,	
1996;	Stamatakis	&	Stuber,	2012).	Indeed,	a	variety	of	studies	have	shown	that	the	
LHb	exhibits	increased	neuronal	activity	under	adverse	conditions.	In	an	experiment	
using	fMRI	imaging	techniques	with	human	subjects,	Hennigan	and	colleagues	found	
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that	the	lateral	habenula	is	active	during	“punishment”	trials	where	participants	
received	mild	foot	shocks	(Hennigan,	D’Ardenne,	&	McClure,	2015).	Activation	of	the	
LHb	was	also	found	to	induce	physiological	signs	of	anxiety	in	rats,	such	as	
vasoconstriction	and	brown	adipose	tissue	thermogenesis	(Ootsuka	&	Mohammed,	
2015).	Likewise,	under	conditions	of	heightened	anxiety,	inactivation	of	the	LHb	
decreases	anxiogenic	behaviors	in	rodents	(Gill,	Ghee,	Harper,	&	See,	2013).		
The	LHb	also	appears	to	be	necessary	for	the	long-term	storage	of	memories	
for	adverse	events.	One	study	found	that	pharmacological	inactivation	of	the	LHb	
during	aversion	training	in	rats	could	lead	to	a	loss	of	the	memory	seven	days	later,	
but	not	24	hours	later	(Tomaiuolo,	Gonzalez,	Medina,	&	Piriz,	2014).	This	suggests	
that	while	the	general	memory	of	the	animal	remained	intact	regardless	of	the	LHb	
inactivation,	the	subjective	salience	of	the	experience	was	altered	in	such	a	manner	
as	to	disrupt	long-term	storage	of	the	memory.	
While	all	these	studies	clearly	implicate	the	LHb	in	the	processing	of	aversive	
information,	perhaps	the	most	compelling	study	to	demonstrate	the	link	between	
the	LHb	and	aversion	learning	was	performed	by	Matsumoto	and	Hikosaka	(2007).	In	
their	study,	two	monkeys	were	trained	to	perform	a	visual	eye	movement	task	
wherein	the	animal	had	to	make	quick	saccades	to	a	target	on	screen.	The	targets	
signaled	either	a	reward	for	correct	response,	or	no	reward.	At	certain	time	points	
the	target	meanings	were	switched,	so	that	rewarded	targets	became	non-
rewarded,	and	vice	versa.	During	these	tasks,	electrodes	were	placed	in	multiple	
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cells	of	both	the	LHb	and	midbrain	dopamine	neurons	to	record	spiking	activity.	The	
recordings	clearly	showed	that	LHb	neurons	were	more	active	during	non-rewarded	
trials	than	during	rewarded	trials,	again	suggesting	that	the	LHb	is	more	active	under	
adverse	conditions,	while	the	opposite	was	found	for	DA	cells.	However,	the	cells	of	
the	LHb	showed	the	most	robust	responding	during	trials	where	the	target	meanings	
had	been	switched	from	signaling	reward	to	non-reward.	Here,	the	animals	
expected	that	the	task	would	result	in	a	reward,	but	no	reward	was	earned.	The	
difference	between	the	expected	rewarding	outcome	and	the	actual	outcome	of	no	
reward	caused	significant	increases	in	LHb	activation.	Matsumoto	and	Hikosaka	
(2007)	refer	to	this	as	a	“reward	prediction	error”,	where	an	expected	reward	is	
omitted.	Thus,	it	was	under	circumstances	of	reward	prediction	error	that	the	LHb	
was	found	to	be	most	active,	an	effect	that	has	now	been	replicated	in	other	studies	
and	under	different	conditions	(Bromberg-Martin	&	Hikosaka,	2011;	Bromberg-
Martin,	Matsumoto,	&	Hikosaka,	2010;	Matsumoto	&	Hikosaka,	2007,	2009;	Tian	&	
Uchida,	2015).	Additionally,	human	neuroimaging	studies	of	the	LHb	have	similarly	
shown	enhanced	activity	in	response	to	reward	prediction	errors	(Shepard,	
Holcomb,	&	Gold,	2006;	Ullsperger	&	Cramon,	2003).	
Activation	of	the	LHb	under	these	conditions	also	appears	to	be	linked	to	
inhibited	DA	release	in	the	midbrain.	When	a	reward	prediction	error	occurs,	the	
LHb	is	first	found	to	increase	its	activity,	and	this	is	followed	shortly	thereafter	by	a	
silencing	of	the	DA	neurons	of	the	VTA	(Bromberg-Martin	&	Hikosaka,	2011;	
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Matsumoto	&	Hikosaka,	2007).	The	time-course	of	this	activation	and	subsequent	
silencing	of	distinct	neuronal	populations	is	suggestive	of	a	causal	relationship	
between	the	two	groups.	Indeed,	reciprocal	connections	have	been	found	between	
the	LHb	and	the	VTA	(Gruber,	Kahl,	Lebenheim,	Kowski,	Dittgen,	&	Veh,	2007;	Jhou	
et	al.,	2013),	and	electrical	stimulation	of	LHb	inhibits	VTA	neurons	(Christoph	et	al.,	
1986;	Ji	&	Shepard,	2007).	Inversely,	studies	utilizing	pharmacological	inhibition	of	
LHb	have	found	increased	DA	release	in	striatal	neurons	(Lecourtier,	DeFrancesco,	&	
Moghaddam,	2008).	According	to	Stamatakis	et	al.	(2013),	these	data	suggest	that,	
“LHb	neurons	encode	negative	reward	prediction	errors	and	may	negatively	
modulate	midbrain	dopaminergic	neurons	in	response	to	aversive	events”	
(Stamatakis,	Jennings,	Ung,	Blair,	Weinberg,	Neve,	Boyce,	Mattis,	Ramakrishnan,	
Deisseroth,	&	Stuber,	2013).		
Recent	studies	have	proposed	that	this	inhibition	of	midbrain	DA	neurons	by	
the	LHb	may	facilitate	the	onset	of	cocaine’s	negative	properties	(Friedman,	Lax,	
Dikshtein,	Abraham,	Flaumenhaft,	Sudai,	Ben-Tzion,	Ami-Ad,	Yaka,	&	Yadid,	2010;	
Jhou,	Fields,	Baxter,	Saper,	&	Holland,	2009),	as	lateral	habenular	function	is	also	
affected	by	exposure	to	drugs	of	abuse.	For	example,	direct	application	of	cocaine	to	
the	LHb	results	in	increases	in	neuronal	activation	within	this	region	(Zuo,	Chen,	
Wang,	&	Ye,	2013).	The	mechanism	through	which	the	LHb	modulation	of	DA	occurs	
is	thought	to	be	via	a	region	called	the	the	rostro-medial	tegmental	nucleus	(RMTg),	
which	sits	adjacent	to,	and	is	a	major	source	of	inhibitory	GABAergic	projections	
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onto	the	VTA	(Balcita-Pedicino,	Omelchenko,	Bell,	&	Sesack,	2011;	Jhou,	Fields,	et	
al.,	2009;	Jhou,	Geisler,	et	al.,	2009).	Thus,	activation	the	LHb	is	believed	to	inhibit	
the	VTA	via	glutamatergic	activation	of	the	RMTg,	which	in	turn	inhibits	cell	firing	
within	the	VTA	(Good,	Wang,	Chen,	Mejias-Aponte,	Hoffman,	&	Lupica,	2013;	Jhou,	
Fields,	et	al.,	2009;	Jhou,	Geisler,	et	al.,	2009;	Kowski,	Veh,	&	Weiss,	2009;	
Omelchenko,	Bell,	&	Sesack,	2009).	This	may	then	be	the	first	step	in	“turning	off”	
the	initial	reward	signals	produced	by	DA	cells	within	the	VTA,	thereby	unmasking	
the	underlying	negative	effects	of	cocaine	(or,	for	Solomon	&	Corbitt,	the	“B”	
process).	
To	complete	the	circuit,	it	has	now	been	demonstrated	that	DA	cells	within	
the	VTA	themselves	project	back	to	the	LHb	(Gruber	et	al.,	2007;	Phillipson	&	
Griffith,	1980;	Skagerberg,	Lindvall,	&	Björklund,	1984),	potentially	forming	a	
negative-feedback	loop	through	which	the	encoding	of	both	appetitive	and	aversive	
information	can	interact	and	restore	a	homeostatic	balance.	Indeed,	Jhou	et	al.	
(2013)	has	shown	that	a	subset	of	LHb	neurons	exhibit	biphasic	responses	to	i.v.	
cocaine	with	an	initial	inhibition	(thereby	decreasing	the	LHb-RMTg	inhibition	of	the	
VTA	and	permitting	the	reward	signal	to	predominate)	followed	by	a	delayed	
excitation	whose	timing	parallels	cocaine’s	shift	from	rewarding	to	aversive	
(Ettenberg,	2004;	Ettenberg	et	al.,	1999;	Jhou	et	al.,	2013).		
Although	much	of	the	research	on	the	LHb	has	been	focused	on	its	
connection	and	relationship	with	the	RMTg/VTA	DA	system,	including	work	from	our	
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own	laboratory	that	explored	the	role	of	Dopamine-D4	receptors	in	the	LHb	(Shelton,	
Bogyo,	Schick,	&	Ettenberg,	2016),	it	has	also	long	been	known	that	the	habenula	
has	prominent	reciprocal	projections	to	both	the	dorsal	(DRN)	and	median	(MRN)	
raphé	nuclei	of	the	brainstem	(Lidov	&	Molliver,	1982;	Luo,	Zhang,	Li,	Yang,	Sun,	&	
Zhao,	2015;	Metzger,	Bueno,	&	Lima,	2017).	Recent	anatomical	investigations	of	this	
region	have	revealed	that	it	is	the	medial	portions	of	the	LHb	that	receive	direct	
serotonergic	innervation,	and	in	turn	send	projections	to	acetylcholine-	(ACh),	DA-	
and	serotonin-	(5-HT)	releasing	cells	of	the	midbrain	and	hindbrain.	While	it	is	the	
more	lateral	portion	of	the	LHb		that	synapse	on	the	GABA-ergic	cells	of	the	RMTg,	
which	in	turn	exerts	inhibition	upon	both	the	DA	cells	of	the	VTA,	as	well	as	on	
serotonergic	cells	located	in	both	the	dorsal	and	median	raphé	nuclei	(Metzger	et	
al.,	2017).	Thus,	the	LHb	is	in	a	prime	position	to	regulate	the	brain	serotoninergic	
system	through	both	direct	and	indirect	pathways.	
The	precise	neuronal	mechanism	by	which	this	region	mediates	the	
anxiogenic	response	to	cocaine	remains	under	investigation,	and	forms	the	basis	of	
this	dissertation’s	investigation	into	the	role	of	5-HT	in	the	LHb	and	its	involvement	
in	the	aversive	effects	of	cocaine.				
1.5	Cocaine	and	Serotonin	(5-HT)	
The	neuropharmacological	actions	of	cocaine	are	predominately	mediated	by	
the	drug’s	inhibitory	action	at	the	monoamine	transporters:	DAT,	NET,	and	SERT,	
respectively.	Although	cocaine	is	traditionally	thought	of	as	a	prototypical	DA	
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reuptake	Inhibitor,	it	actually	has	approximately	equal	affinity	for	all	three	
monamine	transporters,	and	if	anything,	is	slightly	more	selective	at	5-HT	than	DA	or	
NE	synapses	(Cunningham,	Paris,	&	Goeders,	1992a,	1992b;	Filip,	Alenina,	Bader,	&	
Przegaliński,	2010;	Walsh	&	Cunningham,	1997).	Additionally,	5-HT	has	been	
strongly	linked	to	the	development	and	expression	of	anxiety-like	behavior	(Abrams,	
Johnson,	Hay-Schmidt,	Mikkelsen,	Shekhar,	&	Lowry,	2005;	Sena,	Bueno,	Pobbe,	
Andrade,	Zangrossi,	&	Viana,	2003;	Watson	&	Man,	2000),	making	serotonin	a	prime	
candidate	to	investigate	in	the	anxiogenic	effects	of	cocaine.	Consistent	with	this	
hypothesis	are	prior	studies	from	our	own	laboratory	demonstrating	that	
inactivation	of	5-HT	cell	bodies	in	the	DRN	(Ettenberg,	Ofer,	&	Mueller,	2011)	and	
systemic	treatment	with	the	5-HT1A	partial	agonist,	buspirone	(Ettenberg	&	Bernardi,	
2006),	reduced	the	development	of	approach/avoidance	“retreat”	behavior	in	the	
runway	model	of	cocaine	self-administration.	Using	a	Conditioned	Place	
Preference/Conditioned	Place	Aversion(CPP/CPA)	paradigm,	buspirone	was	also	
effective	at	selectively	diminishing	the	delayed	aversive	effects	of	the	drug,	while	
leaving	the	initial	positive	effects	intact	(Ettenberg	&	Bernardi,	2007).		
The	BNST	receives	dense	serotonergic	innervation	from	the	dorsal	raphé	
nucleus	(See	Fig	1.2)	and	expresses	multiple	inhibitory	and	excitatory	5-HT	receptor	
subtypes	(Guo,	Hammack,	Hazra,	Levita,	&	Rainnie,	2009;	Hammack,	Guo,	Hazra,	
Dabrowska,	Myers,	&	Rainnie,	2009;	Hazra,	Guo,	Dabrowska,	&	Rainnie,	2012).	Of	
particular	interest	is	the	5-HT1B	autoreceptor,	whose	activation	serves	to	decrease	5-
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HT	release	from	the	pre-synaptic	serotonergic	cell	at	the	synapse	(Adell,	Celada,	&	
Artigas,	2001;	Sari,	Lefèvre,	Bancila,	Quignon,	Miquel,	Langlois,	Hamon,	&	Vergé,	
1997).	Whole-tissue	samples	of	BNST	show	relatively	high	levels	of	expression	of	5-
HT1B	mRNA,	whereas	single	cells	from	the	same	region	do	not	express	this	transcript	
(Guo	et	al.,	2009).	These	findings	indicate	that	5-HT1B	receptors	within	the	BNST	are	
likely	localized	presynaptically	and	so	manipulations	targeted	at	these	receptors	
should	be	selective	to	5-HT	projections	into	the	BNST.	
In	vitro	experiments	to	assess	the	neuronal	response	of	BNST	cells	to	
serotonin	have	shown	that	this	region	has	a	heterogenous	response,	with	some	
neurons	hyperpolarizing,	some	depolarizing,	and	yet	another	group	that	had	a	mixed	
response	with	an	initial	hyperpolarization	followed	by	depolarization	(Hammack	et	
al.,	2009).	In	the	very	same	study,	the	authors	demonstrated	that	chronic	stress	
changes	the	overall	profile	from	one	that	favors	an	inhibitory	response	to	5-HT,	
towards	one	where	5-HT	produces	excitation.	They	note	the	potential	implications	
for	anxiety	and	propose	a	model	where	under	normal	conditions,	5-HT	release	in	the	
BNST	is	inhibitory,	which	serves	to	decrease	anxiety.	However,	in	animals	exposed	to	
chronic	stress,	the	receptor	expression	profile	changes	to	favor	excitation,	turning	
what	was	a	negative	feedback	loop	with	the	DRN	into	a	positive	feedback	loop,	that	
turns	an	anxiolytic	circuit	into	an	anxiogenic	one	(Hammack	et	al.,	2009).	For	this	
dissertation,	it	is	hypothesized	that	much	like	the	effects	of	chronic	stress,	chronic	
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exposure	to	cocaine	will	also	shift	the	BNST	response	to	5-HT	from	being	primarily	
anxiolytic	to	primarily	anxiogenic.	
Similar	to	the	BNST,	the	LHb	also	expresses	a	wide	variety	of	5-HT	receptors,	
including	the	5-HT1,	5-HT2,	5-HT3,	5-HT5,	and	5-HT7	families	(Metzger	et	al.,	2017).	
Again,	the	current	dissertation	focuses	in	particular	on	the	presence	of	inhibitory	5-
HT1B	receptors	in	the	LHb	(Tchenio,	Valentinova,	&	Mameli,	2016;	Wagner,	Bernard,	
Derst,	French,	&	Veh,	2016;	Wagner,	French,	&	Veh,	2016).	The	5-HT1B	receptor	is	an	
inhibitory	Gi-coupled	receptor	that	is	primarily	located	on	axon	terminals	as	an	auto-	
or	hetero-receptor	(Boschert,	Aït.	Amara,	Segu,	&	Hen,	1994).	Therefore,	by	
targeting	the	5-HT1B	autoreceptors	with	a	selective	5-HT1B	agonist,	it	should	be	
possible	to	decrease	the	cocaine-induced	5-HT	release	with	local	infusion	of	the	
drug.	Indeed,	microdialysis	studies	have	demonstrated	that	local	application	of	a	5-
HT1B	agonist	into	the	LHb	is	capable	of	decreasing	5-HT	release	(Adell	et	al.,	2001).	
Additionally,	systemic	treatment	with	5-HT1B	agonists	has	been	shown	to	produce	
anxiolytic-like	effects	across	multiple	behavioral	tests	(Chojnacka-Wojcik,	Klodzinska,	
&	Tatarczynska,	2005;	Tatarczynska,	2004),	which	further	supports	the	hypothesis	
that	this	receptor	represents	an	ideal	target	to	modulate	the	anxiogenic	response	to	
cocaine.	
The	5-HT	response	of	neurons	in	the	LHb	is	complex,	and	still	not	completely	
understood.	A	recent	review	by	Metzger,	Bueno,	and	Lima	(2017)	gives	an	in-depth	
overview	of	the	relationship	between	serotonin	and	the	LHb.	Briefly,	they	describe	
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how	the	LHb	has	two	major	outputs	that	can	regulate	the	brain	5-HT	system:	one,	
originating	in	the	medial	LHb	that	directly	innervates	the	DRN,	and	a	second	indirect	
pathway,	from	the	lateral	LHb	that	can	modulate	the	DRN/MRN	indirectly	via	
activation	of	GABAergic	cells	of	the	RMTg	(Metzger	et	al.,	2017).	They	also	note	the	
existence	of	a	reciprocal	connection	from	the	DRN/MRN	back	to	the	LHb.	However,	
this	serotonergic	pathway	does	appear	to	restrict	its	projections	to	only	the	medial	
subsection	of	the	LHb,	as	well	as	the	medial	habenula,	with	only	a	very	sparse	
labeling	of	5-HT	stained	fibers	in	the	more	lateral	regions.	The	authors	also	make	
note	of	the	implications	for	a	potential	dysfunction	in	this	circuitry	to	be	involved	
with	the	pathophysiology	of	anxiety	and	depression	(Metzger	et	al.,	2017).		
The	LHb	has	also	been	implicated	in	the	aversive	effects	of	cocaine.	As	
referenced	above,	the	study	by	Jhou	and	colleagues	(2013)	showed	that	cocaine	
produces	a	biphasic	response	in	LHb	neurons,	with	an	initial	hyperpolarization,	
followed	by	a	delayed	depolarization.	They	also	found	that	by	using	optogenetic	
inhibition	to	silence	the	LHb	10-20	mins	following	cocaine	administration,	they	could	
block	the	emergence	of	approach-avoidance	retreat	behavior,	using	a	very	similar	
runway	model	of	self-administration	to	the	one	described	in	this	thesis	(Jhou	et	al.,	
2013).	This	study	provides	further	evidence	in	support	of	the	previously	described	
“Opponent	Process	Theory”	by	Solomon	&	Corbitt	(1974),	which	postulates	that	any	
affective	response	will	be	followed	shortly	after	with	an	opposite	opponent	process	
to	bring	the	organism	back	to	a	homeostatic	baseline.	Additionally,	this	experiment	
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further	implicates	the	lateral	habenula	as	having	a	major	role	in	mediating	the	
delayed	aversive	effects	of	cocaine.	
1.6	Specific	Aims	
It	is	evident	that	cocaine	produces	an	initial	rewarding	state	of	euphoria,	
followed	shortly	after	by	an	anxiogenic,	dysphoric	“crash”	in	both	animals	and	
humans.	While	the	positive	effects	of	cocaine	have	been	thoroughly	studied	over	the	
decades,	much	less	attention	has	been	directed	at	understanding	the	drug’s	
negative	effects.	Cocaine	is	known	to	have	potent	effects	on	the	brain’s	5-HT	
systems,	which	have	been	strongly	implicated	in	disorders	involving	anxiety	and	
depression.	Thus,	the	overarching	goal	of	this	dissertation	was	to	better	understand	
the	relationship	between	cocaine	and	5-HT	vis-a-vis	cocaine’s	negative	anxiogenic	
actions,	with	a	focus	on	the	BNST	and	LHb	--	two	brain	regions	that	have	recently	
come	into	focus	as	potential	targets	for	understanding	the	aversive	effects	of	the	
drug.	With	that	in	mind,	using	intracerebral	pharmacological	manipulation	of	5-HT	
release	and	the	application	of	selective	5-HT	lesions,	the	research	described	herein	
was	devised	to	assess	the	role	of	5-HT	within	these	two	brain	regions	–	BNST	and	the	
LHb	--	in	contributing	to	the	anxiogenic	effects	of	cocaine.	The	results	of	this	
research	were	intended	to	add	important	insights	into	the	role	of	5-HT	in	mediating	
the	well-known,	but	often	ignored,	anxiogenic	effects	of	self-administered	cocaine.	
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Chapter	2.	General	Methodology	
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2.1	Subjects	
Subjects	for	all	experiments	were	adult	male	albino	Sprague-Dawley	rats	
weighing	approximately	275-300g	at	the	time	of	surgery.	Rats	were	obtained	from	
Charles	River	Laboratories	(Hollister,	California,	USA)	and	were	pair-housed	in	
hanging	plastic	cages	within	a	temperature-controlled	(23º	C)	vivarium	maintained	
under	a	reverse	12-hour	light-dark	cycle	(lights	off	at	0800h).		Animals	were	
provided	ad	libitum	access	to	food	(Purina	Rat	Chow)	and	water	throughout	the	
duration	of	each	experiment.	All	animal	handling	and	procedures	adhered	to	the	NIH	
Guide	for	the	Care	and	Use	of	Laboratory	Animals	and	were	reviewed	and	approved	
by	the	University	of	California	at	Santa	Barbara’s	Institutional	Animal	Care	and	Use	
Committee.	
2.2	Surgical	Procedures	
Each	subject	was	deeply	anesthetized	with	an	intramuscular	injection	of	
ketamine	and	xylazine	(56.25	and	7.5	mg/kg,	respectively;	Abbott	Laboratories)	and	
fitted	with	an	indwelling	intravenous	(i.v.)	catheter	(13	mm	of	microrenathane	
tubing,	0.014	mm	inner	diameter,	0.33	mm	outer	diameter;	Braintree	Scientific)	
inserted	into	the	right	jugular	vein,	secured	in	place	by	silk	sutures,	and	
subcutaneously	(s.c.)	passed	to	a	threaded	guide	cannula	(catalog	#313G;	Plastics	
One)	that	exited	though	a	2	mm	hole	on	the	animal’s	back.	The	guide	cannula	was	
cemented	to	a	3.0	cm	square	piece	of	Mersiline	mesh	(Bard;	Warwick,	RI)	that	was	
laid	flat	subcutaneously	on	the	animal’s	back	where	it	was	secured	with	surgical	
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glue.	While	still	anesthetized,	each	rat	was	then	fitted	with	bilateral	intracranial	
guide	cannulae	(22	gauge,	9	mm;	Catalog	#313GA/SPC;	Plastics	One)	stereotaxically	
aimed	1.0	mm	above	the	targeted	brain	region,	using	coordinates	derived	from	the	
brain	atlas	of	Paxinos	and	Watson	(2007).	The	coordinates	used	for	intracerebral	
cannula	implantation	were	as	follows:	relative	to	bregma,	AP	−0.4,	ML	±3.5,	and	DV	
−6.2	from	skull	surface	with	a	lateral	inclination	of	15°	for	the	BNST,	and	AP	−3.4,	ML	
±1.5,	and	DV	−3.2		from	skull	surface	with	a	lateral	inclination	of	11°	for	the	LHb	
(Paxinos	&	Watson,	2007).	During	surgery,	subjects	received	the	non-opiate	
analgesic	meloxicam,	(2.0	mg/kg	s.c.	at	a	concentration	of	5.0	mg/ml	in	saline)	to	
control	for	post-surgical	pain	in	addition	to	buprenorphine	HCl	(0.05	mg/kg,	0.3	
mg/ml),	and	saline	for	rehydration	(3.0	ml	s.c.).	The	catheters	were	flushed	with	the	
antibiotics	cefazolin	+	gentamycin	(0.25	ml	of	1	mg/ml	&	5.0	mg/ml,	respectively)	to	
prevent	infection	and	heparinized	saline	(6.25	IU,	0.1	ml	i.v.)	to	retain	patency.		
After	surgery,	catheter	patency	was	maintained	via	daily	flushing	with	0.1ml	
cefazolin	and	gentamycin	(1.0	mg/ml	&	5.0	mg/ml,	respectively)	followed	by	0.1	ml	
of	heparinized	0.9%	physiological	saline.	Animals	were	allowed	to	recover	for	at	
least	7	days	prior	to	behavioral	testing.	Catheter	patency	was	periodically	assessed	
through	observation	of	the	loss	of	the	righting	reflex	following	an	i.v.	injection	of	the	
fast-acting	barbiturate,	methohexital	(brevital,	2.0	mg/kg/	0.1	ml).	Rats	that	were	
unresponsive	to	brevital	prior	to	the	start	of	behavioral	testing	were	re-implanted	
with	a	new	catheter	using	the	left	jugular	vein	and	given	additional	days	for	
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recovery.	Catheter	patency	failure	during	the	course	of	behavioral	testing	resulted	in	
subject	removal	from	the	data	analysis.		
2.2	Apparatus	
2.2.1	Runway	Model	of	Drug	Self-Administration	
	 Most	experiments	described	in	this	dissertation	employed	the	Runway	
Model	of	Cocaine	Self-Administration,	as	previously	described	in	Chapter	1	(section	
1.4).	Experiments	took	place	in	two	identical	wooden	straight	arm	runways	that	
were	custom	built	for	rodent	drug	self-administration	(See	Fig	2.1).	As	originally	
described	by	Geist	and	Ettenberg,	(1990),	each	apparatus	measured	155	cm	(L)	×	15	
cm	(W)	×	40	cm	(H).	On	opposite	ends	of	the	straight	alley	were	identically	sized	
start	and	goal	boxes	(each	measuring	24	cm	×	25	cm	×	40	cm),	each	separated	from	
the	middle	runway	section	of	the	apparatus	by	retractable	doors.	Along	the	interior	
length	of	the	alley	were	13	infrared	photodetector-	emitter	pairs	positioned	in	the	
walls	16	cm	apart	from	one	another.	Input	from	these	photocells	was	fed	through	an	
Any-Maze	interface	(Stoetling)	to	a	laptop	computer	running	AnyMaze	software,	
which	recorded	the	subjects’	location	in	the	runway	in	real	time	throughout	each	
trial.	Along	the	top	of	the	alley	were	two	magnetic	rails	that	ran	the	entire	length	of	
the	apparatus.	These	rails	were	aligned	such	that	their	polarity	would	repel	a	small	
circular	disk	magnet	that	is	attached	to	a	flow-through	swivel	(Instech),	mounted	
within	a	circular	doughnut-shaped	piece	of	plastic	that	prevented	the	swivel	from	
falling	through	between	the	rails.	The	opposing	polarities	of	the	rail	magnets	and	the	
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magnet	affixed	to	the	plastic	holder	kept	the	entire	swivel	device	floating	a	few	cm	
above	the	rail	surface	(see	Figure	2.1).		This	magnetically	levitating	swivel	design	
allowed	an	animal	to	be	tethered	to	a	syringe	pump	for	drug	infusion,	while	
permitting	free	movement	throughout	the	apparatus	with	little	to	no	friction	
impeding	performance.	
2.2.2	Locomotor	Activity	Chambers	
	 Locomotor	behavior	(total	distance	traveled,	cm)	was	measured	in	12	
identical	Plexiglas	chambers	each	measuring	20	cm	(L)	×	40	cm	(W)	×	20	cm	(H)	
(Kinder	Scientific).	Each	test	chamber	was	equipped	with	an	array	of	fifteen	infrared	
photodetector-emitter	pairs	evenly	spaced	along	its	long	axis	and	seven	along	its	
narrow	axis,	all	8	cm	above	the	floor	surface.	Movement	within	the	chamber	
produced	photobeam	interruptions	that	were	recorded	by	a	desktop	computer	
running	Motor	Monitor	software	(Kinder	Scientific).		
2.3	Drugs	
Cocaine	hydrochloride	(provided	by	the	National	Institute	on	Drug	Abuse)	
was	dissolved	in	0.9%	physiological	saline	and	sterile	filtered	through	a	0.22	μm	filter	
(ThermoScientific).	Cocaine	was	diluted	to	a	dose	of	1.0	mg/kg	delivered	in	a	volume	
of	0.1	ml	over	a	period	of	4.6	s	via	a	10	ml	syringe	nested	in	a	motorized	syringe	
pump	(Razel	Scientific	Instruments).	The	dose	of	1.0	mg/kg	i.v.	cocaine	was	chosen	
based	upon	the	results	of	previous	runway	work	from	our	laboratory	(Ettenberg,	
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2004;	Ettenberg	&	Bernardi,	2006;	Raven,	Necessary,	Danluck,	&	Ettenberg,	2000;	
Wenzel	et	al.,	2014,	2011).	
The	5-HT1B	agonist	CP	94,253	dihydrochloride	(Sigma-	Aldrich)	was	prepared	
in	a	vehicle	solution	of	aCSF	(l-ascorbic	acid	0.35	g/L,	NaCl	8.47	g/L,	KCl	.20	g/L,	
MgCl2	.20	g/L,	CaCl2	.18	g/L,	NaH2PO4	.276	g/L,	Na2HPO4	.5362	g/L)	for	intracranial	
infusion.	The	drug	CP	94,253	was	selected	because	it	shows	the	greatest	affinity	for	
5-HT1B	over	other	receptors	in	the	5-HT1	family	(Koe,	Nielsen,	Macor,	&	Heym,	
1992),	and	has	produced	behavioral	effects	in	prior	studies	using	intracranial	
administration	at	comparable	doses	(De	Almeida,	Rosa,	Santos,	Saft,	Benini,	&	
Miczek,	2006;	Veiga	&	Miczek,	2007).	
In	order	to	demonstrate	receptor	specificity,	the	5-HT1B	antagonist	NAS-181	
was	selected	due	to	its	high	affinity	for	the	5-HT1B	receptor	and	ability	to	block	
agonist	binding	(De	Groote,	Klompmakers,	Olivier,	&	Westenberg,	2003;	De	Groote,	
Olivier,	&	Westenberg,	2002;	Stenfors,	Yu,	&	Ross,	2000).	This	drug	was	prepared	in	
the	same	vehicle	and	co-infused	with	5-HT1B	agonist.	
For	lesion	studies,	the	compound	5,7-Dihydroxytryptamine	(5,7-DHT;	
Adipogen)	was	infused	once	at	a	dose	8.0	µg/µl/side.	This	regimen	is	known	to	be	
selectively	neurotoxic	to	serotonergic	cells,	provided	animals	are	pretreated	with		
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Figure	2.1	Schematic	diagram	of	the	runway	self-administration	apparatus	and	the	
flow-through	swivel	assembly.	From	Geist	and	Ettenberg	(1990).	
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25.0	mg/kg	desipramine	to	prevent	5,7	DHT	uptake	into	NE	neurons	(Fletcher,	Korth,	
&	Chambers,	1999;	Izumi,	Ohmura,	Futami,	Matsuzaki,	Kubo,	Yoshida,	&	Yoshioka,	
2012;	Macedo,	Castilho,	de	Souza	e	Silva,	&	Brandão,	2002;	Nelson,	Thur,	Marsden,	
&	Cassaday,	2012).	
2.4	General	Procedures		
	 For	an	overview	of	the	experimental	timeline,	see	Fig	2.2.		
2.4.1	Runway	Testing	
Prior	to	the	first	cocaine-reinforced	trial,	subjects	were	individually	placed	
into	the	start	box	and	permitted	to	freely	explore	the	runway	for	10	min	to	allow	for	
acclimation	to	the	apparatus	(the	goal	door	remained	closed	to	prevent	entry	into	
the	goal	box).	The	first	of	16	single	daily	runway	trials	began	the	following	day.		
During	each	trial,	subjects	were	connected	to	the	drug	delivery	system	and	placed	
into	the	start	box	where,	after	5	s,	the	start	door	was	opened	and	the	trial	initiated.	
Upon	entry	into	the	goal	box,	the	goal	door	was	(to	prevent	retracing)	and	an	i.v.	
infusion	of	1.0	mg/kg	cocaine	(in	0.1	ml	over	4.6	s)	was	administered.	After	5	min,	
subjects	were	removed	from	the	goal	box	and	returned	to	their	home	cages.	On	the	
rare	occasion	that	an	animal	did	not	enter	the	goal	box	within	10	min,	it	was	gently	
encouraged	(pushed	from	behind)	to	enter	the	goal	box,	where	it	then	received	an	
i.v.	injection	of	cocaine.	All	trials	for	a	given	subject	were	conducted	in	the	same	
apparatus.	To	maintain	catheter	patency,	animals	were	flushed	with	0.1	ml	of	
	 40	
cefazolin/gentamycin	followed	by	0.1	ml	heparinized	saline	after	removal	from	the	
apparatus.		
2.4.2	Locomotor	Testing	
	
To	ensure	that	central	manipulations	did	not	produce	nonspecific	alterations	
in	the	response	capacity	of	the	subjects,	they	were	examined	in	a	test	of	
spontaneous	locomotor	activity	following	completion	of	runway	testing.	At	the	start	
of	testing,	all	animals	were	allowed	to	acclimate	to	the	locomotor	chambers	for	60	
min.	Rats	were	then	removed	from	the	test	chambers,	administered	the	same	
bilateral	microinjections	that	they	had	received	previously	during	runway	testing,	
and	immediately	returned	to	the	locomotor	chambers	for	an	additional	15-min	test	
session.		
2.4.3	Serotonin	5-HT1B	agonist/antagonist	treatments	
For	these	experiments,	animals	received	intracranial	microinfusions	prior	to	
each	of	the	16	daily	trials	in	the	runway.	The	infusions	were	administered	slowly	
over	120	s	using	a	25	μl	Hamilton	syringe	that	was	seated	in	a	motorized	syringe	
pump	(KD	Scientific).	The	syringe	was	connected	via	PE20	tubing	to	28-gauge	
internal	cannula	(catalog	#313LI/SPC	Plastics	One)	that,	when	inserted	into	the	
implanted	intracranial	guide	cannula,	projected	2	mm	beyond	the	tip	of	the	guide	
cannula.	The	internal	cannula	were	left	in	place	for	60	s	post-infusion	to	permit	
diffusion	of	the	drug	away	from	the	injection	tip.	Seven	minutes	after	the	infusion	
cannula	was	removed,	each	subject	was	moved	to	the	runway	apparatus,	connected		
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Figure	2.2	Experimental	Timeline	
After	arrival	in	the	vivarium,	animals	were	acclimated	for	one	week	with	daily	
handling	before	beginning	the	experiment.		During	week	2	animals	underwent	
surgery	for	implantation	of	IC	cannula,	or	5-HT	lesion	(red	+),	and	were	allowed	a	full	
week	to	recover	before	their	first	trial.	Prior	to	the	first	day	of	testing,	animals	had	
one	habituation	trial	in	the	runway,	followed	by	16	days	of	testing.	Animals	in	the	
drug	treatment	experiments	(red	*)	were	administered	an	intracranial	pretreatment	
10	mins	prior	to	the	start	of	testing	on	each	day	during	the	16-day	period.	
Locomotor	behavior	was	assessed	24	hours	after	the	last	runway	trial.	After	that,	
animals	were	euthanized	and	their	brains	collected	for	histological	analysis.		 	
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to	the	i.v.	drug	delivery	system,	and	placed	into	the	start	box	where,	after	5	s,	the	
start	door	was	opened	and	the	trial	initiated.	
2.4.4	Serotonin-selective	Neurotoxic	Lesion	Treatment	
	 Animals	participating	in	the	5-HT	neurotoxic	lesion	experiments	were	
administer	an	intracranial	treatment	of	either	the	5-HT	neurotoxin	5,7-DHT	or	
vehicle,	on	only	one	single	occasion-	during	surgery.	Since	subjects	each	received	a	
single	infusion,	they	were	not	fitted	with	internal	cannula.	The	intracranial	infusion	
was	delivered	while	the	animal	was	under	anesthesia	for	the	catheter	surgery,	using	
the	same	stereotaxic	surgical	procedures	and	coordinates	described	above,	except	
that	the	cannula	was	removed	after	the	infusion	and	the	animals	were	then	allowed	
to	recover.	Infusions	were	delivered	in	a	volume	of	1.0	µl	over	5	mins	(left	in	place	
an	additional	2	mins	to	allow	drug	diffusion	away	from	the	cannula	tip).	
	 Since	these	animals	did	not	require	microinjections	prior	to	each	of	the	
runway	trials,	the	procedure	for	these	experiments	began	with	each	animal	simply	
being	removed	from	its	home	cage,	their	catheters	flushed	with	saline	to	clear	any	
blockages,	and	then	placed	in	the	runway	apparatus	for	testing.	All	testing	
parameters	for	these	animals	were	identical	to	those	described	for	the	
pharmacological	manipulations.	
2.5	Histology	
After	completion	of	behavioral	testing,	animals	were	euthanized	with	an	
overdose	of	sodium	pentobarbital	and	phenytoin	sodium	solution	(Euthasol;	Virbac)	
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and	perfused	through	the	heart	with	120	mL	phosphate-buffered	saline	(PBS)	
followed	by	120	mL	4%	paraformaldehyde	(PFA)	in	PBS.	Brains	were	removed	and	
post-fixed	in	4%	PFA,	after	which	cannula	placements	were	determined	from	Nissl-
stained	40	μm	frozen	coronal	sections.	Subjects	were	excluded	from	analysis	if	there	
was	sufficient	evidence	of	necrosis	at	the	injection	site,	or	if	the	injection	site	landed	
outside	the	targeted	region.	These	exclusions	were	determined	by	a	trained	
observer	blind	to	the	treatment	conditions	of	the	animals.	
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Chapter	3.	Cocaine,	Serotonin,	and	the	Bed	Nucleus	of	the	Stria	Terminalis	
(BNST)	
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3.1	Introduction	
The	current	experiment	employed	the	self-administration	runway	detailed	in	
Chapter	2	to	examine	the	role	of	serotonin	release	within	the	BNST	in	subserving	
cocaine’s	negative/anxiogenic	effects.	As	described	in	Chapters	1	&	2,	animals	
running	an	alley	once	a	day	for	i.v.	cocaine	quickly	approach,	but	then	stop	at,	the	
goal	box	entryway	and	retreat	back	toward	the	start	box	(Ettenberg	&	Geist,	1991,	
1993).	As	described	in	Chapter	1,	this	unique	pattern	of	“retreat”	behavior	has	been	
shown	to	reflect	an	approach–avoidance	conflict	stemming	from	mixed	positive	
(rewarding)	and	negative	(anxiogenic)	associations	with	the	cocaine-paired	goal	box	
(Ettenberg	&	Geist,	1991;	Ettenberg	et	al.,	1999;	Geist	&	Ettenberg,	1997;	Guzman	&	
Ettenberg,	2007;	see	reviews	by	Ettenberg,	2004,	2009).	As	again	described	in	
Chapter	1,	The	BNST	contains	serotonergic	synapses	(Freedman	&	Shi,	2001;	Guo	et	
al.,	2009;	Hammack	et	al.,	2009;	Hazra	et	al.,	2012),	where	cocaine	acts	to	inhibit	the	
activity	of	the	presynaptic	transporter	thereby	enhancing	the	impact	of	5-HT	release	
at	the	synapse	(Filip	et	al.,	2010;	D.	D.	Han	&	Gu,	2006;	Müller	&	Huston,	2006;	
Reith,	Meisler,	Sershen,	&	Lajtha,	1986).	Additionally,	the	BNST	shows	elevated	
levels	of	the	stress	neuropeptide	CRF	in	response	to	cocaine	(Kash,	Pleil,	
Marcinkiewcz,	Lowery-gionta,	Crowley,	Mazzone,	Sugam,	Hardaway,	&	Mcelligott,	
2015),	is	responsive	to	negative	emotional	and	anxiogenic	stimuli	(Adhikari,	2014;	
Davis,	2006;	Kim,	Adhikari,	Lee,	Marshel,	Kim,	Mallory,	Lo,	Pak,	Mattis,	Lim,	Malenka,	
Warden,	Neve,	Tye,	&	Deisseroth,	2013;	Ventura-Silva,	Pêgo,	Sousa,	Marques,	
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Rodrigues,	Marques,	Cerqueira,	Almeida,	&	Sousa,	2012),	and	has	been	implicated	in	
the	aversive	effects	of	cocaine	withdrawal	(Erb,	2010;	Koob,	2008).	The	goal	of	the	
present	experiment	was,	therefore,	to	investigate	the	functional	role	of	5-HT	
signaling	within	the	BNST	in	modulating	the	negative/aversive	actions	of	cocaine	by	
examining	the	development	of	cocaine-induced	approach–avoidance	retreat	
behaviors	in	animals	treated	with	a	5-HT1B	auto-receptor	agonist.		
3.2	Materials	and	Methods	
3.2.1	Subjects	
	 The	subjects	were	127	male	Sprague-Dawley	rats,	with	housing	and	living	
conditions	as	described	in	Chapter	2.	
3.2.2	Surgery	
	 Surgical	procedures	were	performed	as	outlined	in	Chapter	2.	Briefly,	rats	
were	fitted	with	both	an	i.v.	jugular	catheter	and	bilateral	intracranial	guide	cannula	
aimed	just	above	the	BNST.			
3.2.3	Drugs	
The	drugs	employed	in	this	experiment	were:	cocaine	hydrochloride	(1.0	
mg/kg	i.v.)	served	as	the	reinforcer	in	the	runway	test,	the	effects	of	which	were	
examined	after	pretreatment	with	the	5-HT1B	auto-receptor	agonist	CP	94,253	
dihydrochloride,	(0.25,	0.5,	or	1.0	µg/0.5	µl	i.c.).	Significant	effects	of	the	agonist	
were	then	challenged	by	co-administration	of	the	agonist	plus	the	selective	5-HT1B	
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antagonist	NAS-181	(0.0,	0.1,	or	1.0	μg/0.5	µl	i.c.).	All	the	drugs	were	prepared	and	
administered	as	described	in	Chapter	2.3.				
3.2.4	Procedures	
Subjects	were	acclimated	to	the	apparatus	on	a	single	non-reinforced	trial	for	
10	min	after	which	(i.e.,	the	next	day),	the	first	of	16	single	daily	runway	trials	was	
initiated	(see	Fig	2.2	for	the	experimental	timeline).		Three	separate	experiments	
were	performed:	in	Experiment	I,	CP	94,253	was	delivered	as	a	pretreatment	(10	
min	prior	to	each	runway	trial);	Experiment	II	was	conducted	in	the	same	manner,	
except	CP	94,253	was	delivered	as	a	post-treatment	(5	min	after	each	runway	trial);	
and	in	Experiment	III	the	behavioral	effects	of	the	agonist	drug	were	challenged	by	
co-administration	of	the	selective	5-HT1B	antagonist,	NAS-181.	
In	Experiment	I,	the	subjects	were	administered	bilateral	intra-BNST	infusions	
of	one	of	three	doses	of	CP	94,253	or	vehicle	prior	to	each	runway	trial.	Animals	
were	free	to	traverse	the	runway	to	earn	an	i.v.	infusion	of	cocaine	upon	goal	box	
entry.	On	the	rare	occasion	that	an	animal	did	not	enter	the	goal	box	within	10	min,	
it	was	gently	encouraged	(pushed	from	behind)	to	enter	the	goal	box,	where	it	then	
received	cocaine.	All	trials	for	a	given	subject	were	conducted	in	the	same	
apparatus.	To	maintain	catheter	patency,	animals	were	flushed	with	10	mg/0.1	ml	
timentin	followed	by	0.1	ml	heparinized	saline	after	removal	from	the	apparatus.	
Since	the	anxiogenic	effects	of	i.v.	cocaine	appear	to	peak	at	15-min	post-
injection	(Ettenberg	et	al.,	1999;	Jhou	et	al.,	2013;	Knackstedt	et	al.,	2002),	it	was	
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important	to	examine	the	impact	of	CP	94,253	in	the	BNST	after	the	subjects	had	
experienced	the	initial	rewarding	effects	of	the	cocaine	but	before	the	onset	of	the	
drug’s	anxiogenic	actions—hence	the	treatment	in	Experiment	II	was	applied	5-min	
post-cocaine.	Animals	first	ran	to	and	entered	the	goal	box	where	they	earned	an	i.v.	
injection	of	cocaine,	and	then	were	removed	(after	5	min)	and	administered	either	
0.0	or	1.0	μg	CP	94,253.		
Experiment	III	was	conducted	to	demonstrate	the	selectivity	of	the	agonist’s	
effects	to	the	5-HT1B	receptor.	In	this	protocol,	10	min	prior	to	each	runway	trial,	
animals	were	provided	intra-BNST	bilateral	infusions	of	either	the	vehicle	solution	
alone,	or	a	0.5	μg	dose	of	the	5-HT1B	agonist,	CP	94,253,	co-	administered	with	either	
one	of	the	three	doses	of	the	selective	5-	HT1B	antagonist	NAS-181.	Both	drugs	were	
administered	in	the	same	microinjection	after	which	the	runway	testing	was	
accomplished	as	previously	described.	In	all	experiments,	three	dependent	
measures	were	recorded	on	every	trial.	“Start	latency”—the	time	required	for	the	
animal	to	leave	the	start	box	once	the	start	door	was	opened;	“Run	Time”—the	time	
required	for	the	animal	to	enter	the	goal	box	after	it	had	left	the	start	box;	and	
“Retreats”—the	number	of	times	an	animal	halted	its	forward	motion	and	retreated	
back	toward	the	start	box	by	the	length	of	at	least	two	photodetector-emitters	(i.e.,	
approximately	32	cm).	
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3.2.5	Histology		
As	described	in	Chapter	2,	upon	completion	of	each	experiment,	animals	
were	euthanized	and	their	brains	removed,	sliced,	stained	and	examined	under	
magnification	to	confirm	the	location	of	the	cannula	placements.		
3.3	Results	
3.3.1	Histology	
A	subject’s	inclusion	in	the	study	required	strict	histological	confirmation	of	
bilateral	placements	directly	above	the	target	brain	areas	under	investigation	(see	
Fig.	3.1).	A	total	of	44	animals	successfully	completed	Experiment	I,	an	additional	16	
rats	completed	Experiment	II	and	33	animals	were	used	in	Experiment	III.	
Histological	analyses	identified	16	animals	whose	cannula	placements	required	
removal	from	the	study;	six	had	one	or	more	cannula	located	within	the	lateral	
ventricles	and	four	(not	pictured	in	Fig.	1)	as	their	cannula	were	located	in	regions	
posterior	to	the	data	visualized.	An	additional	six	animals	were	found	to	have	
evidence	of	necrosis	around	the	injection	site	and	were	also	removed	from	the	data	
analyses.		
Of	the	16	animals	in	the	anatomical	control	group,	n=6	had	one	or	more	
cannula	located	within	the	lateral	ventricles	and	n=4	are	not	pictured	in	Fig.	1	as	
their	cannulae	were	located	in	regions	posterior	to	the	data	visualized.	Additionally,	
six	animals	that	were	found	to	have	evidence	of	necrosis	around	the	injection	site	
and	were	also	removed	from	the	data	analyses.	
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	Figure	3.1	Histological	confirmation	of	cannula	placements	
Histological	confirmation	of	cannula	placements	within	the	BNST.		Shaded	areas	
indicate	regions	where	successful	cannula	placements	were	identified.	Locations	
marked	with	an	“O”	indicate	the	placement	of	cannula	tips	within	the	targeted	
region.	The	“X’s”	indicate	placements	that	missed	the	target	and	were	separately	
analyzed	as	anatomical	controls.	Not	pictured	are	6	animals	whose	cannulae	tips	
were	located	within	the	lateral	ventricles	and	4	animals	whose	cannulae	placements	
were	posterior	to	the	target	region.	Numbers	represent	distance	of	coronal	slices	(in	
mm)	posterior	to	bregma.	Figure	adapted	from	Paxinos	and	Watson	(2007).	The	two	
representative	photomicrographs	provide	an	example	of	a	missed	cannula	
placement	(top)	and	a	correctly	placed	cannula	(bottom)	sitting	above	the	BNST.	
Dashed	lines	point	to	the	corresponding	cannula	placement	on	the	schematic	
diagram.	The	darkly-stained	areas	at	the	tip	of	each	cannula	track	reflect	the	tissue	
displaced	by	the	cannula	insertion.		
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3.3.2	Experiment	I	
This	experiment	tested	the	effect	of	intra-BNST	infusions	of	CP	94,253	(0,	
0.25,	0.5,	or	1.0	µg)	on	the	animals’	operant	runway	behavior	performing	for	single	
i.v.	infusions	of	cocaine	(1.0	mg/kg)	reward.	Group	sizes	were	n=12,	8,	12,	12,	
respectively	for	each	of	the	doses	employed.	Figure	3.2	depicts	the	runway	
performance	of	the	animals	during	the	16	days	of	testing.	The	top	panel	shows	the	
mean	(±	SEM)	start	latencies	of	all	groups	across	the	16	runway	trials.	A	two-factor	
(Group	x	Trial)	ANOVA	computed	on	these	data	revealed	a	significant	main	effect	of	
Trial	(F(15,25)	=	3.976,	p	=	.001),	but	no	significant	effect	of	Group	(F(3,39)	=	.177,	p	
=	.912)	and	no	significant	Group	x	Trial	interaction	(F(45,81)	=	.792,	p	=	.802),	
indicating	that	all	groups	reliably	and	comparably	decreased	their	start	latencies	
over	the	course	of	the	experiment.	CP	94,253	did	not,	therefore,	reliably	affect	the	
subjects’	response	initiation	in	the	runway.		
The	run	time	data	for	each	group	are	shown	in	the	middle	panel	of	Figure	
3.2.	The	two-factor	ANOVA	computed	on	these	data	identified	a	statistically	
significant	difference	in	runway	performance	between	the	three	treatment	groups	
(a	main	effect	of	Group;	F(3,40)	=	4.043,	p	=	0.013).	As	the	figure	illustrates,	the	
vehicle	animals	took	the	longest	to	enter	the	goal	box,	the	low	and	intermediate	
doses	of	CP	94,253	produced	the	shortest	run	times,	while	the	high	dose	group	
produced	intermediate	results.	Post	Hoc	analyses	confirmed	that	animals	treated	
with	the	0.25	µg	and	0.5	µg	dose	of	the	5-HT1B	agonist	entered	the	goal	box	sooner	
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Figure	3.2.	Group	Mean	(±SEM)	start	latencies	(top	panel),	run	times	(middle	panel)	
and	approach-avoidance	retreat	behaviors	(bottom	panel)	of	animals	running	a	
straight	alley	once	each	day	for	single	daily	infusions	of	1.0	mg/kg	i.v.	cocaine	after	
pretreatment	with	bilateral	intra-BNST	infusions	(0.0,	0.25,	0.5	or	1.0	µg)	of	the	
5HT1B	agonist,	CP	94,253.	Group	sizes	were	n=12,	8,	12,	12,	respectively.	 	
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than	subjects	in	the	vehicle	group	(Fischer’s	Least	Significant	Difference	[LSD]	Test;	p	
=	.015	and	p	=	.047,	respectively),	while	the	comparison	between	the	high	dose	and	
vehicle	did	not	reach	statistical	significance	(p	=	.198).	There	was	no	reliable	
difference	observed	between	the	doses	of	the	agonist	(p	>	.05).	The	ANOVA	revealed	
no	main	effect	of	Trial;	F(15,26)	=	1.137,	p	=	.374,	and	no	significant	Group	x	Trial	
interaction;	F(45,84)	=	.908,	p	=	.634.		
Analysis	of	the	mean	(±	SEM)	retreat	frequencies	of	the	four	groups	(bottom	
panel	of	Figure	3.2)	revealed	a	significant	main	effect	of	Group	(F(3,40)	=	5.332,	p	=	
.003)	and	a	significant	main	effect	of	Trial	(F(15,26)	=	2.093,	p	=	.048).	However,	the	
Group	x	Trial	interaction	did	not	reach	statistical	significance	(F(45,84)	=	1.010,	p	=	
.474).		Post-hoc	analyses	of	the	retreat	data	using	Fischer’s	LSD	Tests	revealed	that	
animals	receiving	the	0.25µg	(p	=	.005),	0.5	µg	(p	=	.023),	or	1.0	µg	dose	(p	=	.034)	of	
CP	94,253	emitted	fewer	retreats	than	those	in	the	vehicle	control	group,	while	the	
difference	between	the	drug	groups	was	not	significant	(p	>.05).	
3.3.3	Experiment	II	
As	described	above,	the	second	experiment	was	conducted	to	determine	
whether	intra-BNST	administration	of	CP	94,253	5-min	after	the	goal-box	
administration	of	cocaine,	could	prevent	or	attenuate	the	impact	of	cocaine’s	
anxiogenic	effects	which	have	been	shown	to	develop	15	min	post	injection	
(Ettenberg	et	al	1999;	Knackstedt	et	al	2002;	Jhou	et	al	2013).	Each	group	was	
comprised	of	n=8	animals.	Post-cocaine	treatment	with	the	5-HT1B	agonist	
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immediately	after	removal	from	the	goal	box	effectively	reduced	the	frequency	of	
approach	-avoidance	retreats	(see	Figure	3.3).	There	was	a	significant	main	effect	of	
Group	(F(1,14)	=	7.963,	p	=	.014),	Trial	(F(15,210)	=	6.155,	p	<	.001),		and	a	significant	
Group	x	Trial	interaction	(F(15,210)	=	2.586,	p	=	.001).	As	the	figure	illustrates,	while	
both	groups	behaved	comparably	at	the	outset	of	testing,	the	treatment	group	
continued	to	exhibit	relatively	low	levels	of	retreat	behavior	while	the	vehicle-
treated	animals	produced	increased	retreats	as	testing	progressed.		
The	results	for	Start	Latency	and	Run	Time	(data	not	shown)	were	
comparable	to	those	reported	for	Experiment	I.	Start	latencies	decreased	as	testing	
progressed	(a	significant	main	effect	of	Trial;	F(15,210)	=	2.865,	p	<	.001),	and	did	so	
comparably	for	both	groups	(there	was	no	main	effect	of	Group	and	no	Group	x	Trial	
interaction	(p	>	.05	).	Although	Run	Times	tended	to	increase	on	average	across	both	
groups	as	retreat	frequencies	increased	(a	significant	main	effect	of	Trial;	F(15,210)	=	
4.458,	p	<	.001),	the	CP	94,253	group	entered	the	goal	box	sooner	than	the	vehicle-
treated	animals	(a	significant	main	effect	of	Group;	F(1,14)	=	5.246,	p	=	.038).	The	
Group	x	Trial	interaction	was	not	statistically	significant	(p	>	.05).			
3.3.4	Experiment	III	
This	experiment	was	conducted	to	assess	the	efficacy	of	a	highly	selective	5-HT1B	
antagonist	in	reversing	the	effects	of	CP	94,253	observed	in	Experiment	I.	Group	
sizes	were	n=8	for	vehicle	treated	animals,	n=7	in	the	CP	94,253	alone	group,	n=9	for	
the	low	dose	(0.1	µg)	NAS-181,	n=8	for	the	high	dose	(1.0	µg).	The	selective	
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antagonist	NAS-181	was	able	to	block	the	reduction	in	retreats	when	co-
administered	with	the	0.5	µg	intermediate	dose	of	CP	94,253	(see	Fig.	3.4).	Total	
retreat	frequency	was	collapsed	into	Trials	1-8	and	Trials	9-16,	and	a	series	of	one-
tailed	repeated	measures	t-tests	were	conducted	on	these	retreat	frequency	data.	
These	t-tests	revealed	a	significant	increase	in	retreats	over	time	in	the	vehicle	
treated	group	t(8)=-2.442,	p	=	0.020;	as	well	as	with	both	the	low	and	high	doses	of	
NAS-181,	t(8)=-2.140,	p	=	0.033,	and	t(7)=-2.447,	p	=	0.022,	respectively.	
In	the	group	treated	with	CP	94,253	alone,	there	was	no	significant	increase	
in	retreat	behavior,	t(6)=-0.603,	p	=	.284,	which	partially	replicates	the	findings	of	
Experiment	I.	Finally,	the	results	from	the	16	animals	whose	data	were	removed	
after	histological	analyses	were	used	here	as	an	“anatomical	control”	–	these	
animals	all	received	CP	94,253	but	their	cannula	were	deemed	to	be	outside	the	
BNST	target.	These	subjects	performed	comparably	to	cocaine+	vehicle	controls	and	
exhibited	an	increase	in	retreat	frequency	over	trials	[t(15)=-2.569,	p	=	.01]	thereby	
demonstrating	the	critical	importance	of	selective	action	of	the	5-HT1B	agonist	within	
the	BNST.		
3.3.5	Locomotor	Activity	Test	
	 The	effects	of	CP	94,253	on	spontaneous	locomotor	behavior	are	shown	in	
Figure	3.5.	Two	factor	ANOVAs	(Group	x	Time)	were	computed	on	the	data	depicted	
in	the	figure	and	on	the	initial	60	min	baseline/acclimation	period	(data	not	shown).	
As	expected,	there	was	no	difference	in	the	performance	of	the	three	groups	during	
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baseline	(main	effect	of	Group;	p	>	.05)	and	no	Group	x	Time	interaction.	There	was	
a	significant	main	effect	for	Time	(F(11,19)=61.041,	p	<	.001)	indicating	that	all	animals	
showed	normal	and	comparable	habituation	to	the	novel	locomotor-chamber	
environment	prior	to	the	administration	of		CP	94,253.		
The	data	from	the	5-HT1B	agonist	challenge,	using	the	same	dose	each	animal	
received	during	runway	testing,	similarly	confirmed	a	main	effect	of	Time	
(F(2,38)=123.119,	p	<	.001)	as	all	animals	slowed	their	activity	over	time.	Although	
there	appears	to	be	a	slight	suppression	of	locomotor	activity	with	the	lowest	dose,	
this	effect	did	not	reach	statistical	significance	(p	=	.176)	nor	was	there	a	significant	
Group	x	Time	interaction	(p	>	.05).	Thus,	treatment	with	the	5-HT1B	agonist	did	not	
produce	any	reliable	changes	in	locomotion	compared	to	the	vehicle-treated	control	
group.	Nevertheless,	even	the	mild	suppression	of	locomotor	activity	at	the	0.25	µg	
dose	cannot	account	for	the	differences	seen	in	runway	behavior,	as	this	group	
reliably	showed	the	fastest	run	times	and	fewest	retreats.	Locomotor	testing	of	the	
5-HT1B	agonist/antagonist	combination	similarly	showed	no	non-specific	motoric	
effects	of	the	microinjection	(data	not	shown).	
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Figure	3.3	Post-Runway	administration	of	CP	94,253	
Mean	(±SEM)	retreat	frequency	of	animals	treated	with	bilateral	intra-BNST	
infusions	of	0.0	or	1.0	µg/side	of	the	5HT1B	agonist,	CP	94,253,	5-min	after	single	
daily	trials	in	animals	running	a	straight	alley	for	1.0	mg/kg	i.v.	cocaine.	n=8	per	each	
treatment	group.	
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Figure	3.4	Mean	(±SEM)	retreat	frequency	of	animals	running	an	alley	for	single	daily	
iv	infusions	of	1.0	mg/kg	cocaine	delivered	upon	goal-box	entry.	The	group	
designations	refer	to	the	bilateral	intra-BNST	infusions	that	each	group	received	
prior	to	each	trial.	Retreats	were	summed	across	the	first	half	(trials	1-8)	and	second	
half	(trials	9-16)	of	the	experiment.	Group	sizes	were	n=8	for	vehicle	treated	
animals,	n=7	in	the	5-HT1B	autoreceptor	agonist	CP	94,253	(0.5	µg)	group,	n=9	for	
the	CP	94,253	+	the	low	dose	(0.1	µg)	of	the	autoreceptor	antagonist	NAS-181,	n=8	
for	CP	94,253	+	high	dose	of	the	antagonist	(1.0	µg),	and	n=16	for	the	anatomical	
control	group	(which	received	0.5	µg	of	CP	94,253	alone	but	whose	cannulae	were	
histologically	determined	to	have	missed	the	BNST	target	site).	The	data	analyses	
compared	the	performance	of	each	group	during	the	first	8	trials	to	that	on	the	final	
8	trials	*p	<	.05.		 	
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Figure	3.5	Spontaneous	Locomotor	Activity	
The	spontaneous	locomotor	response	(measured	as	distance	traveled	in	cm)	of	
animals	each	pretreated	with	different	doses	of	the	5HT1B	agonist,	CP94,253	(0.0,	
0.25,	0.5	or	1.0	µg/side).	Each	time	point	represents	5	mins	of	locomotor	activity.	
Drug	treatments	produced	no	reliable	alterations	in	locomotor	activity	
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3.4	Conclusions	
A	thorough	discussion	of	the	significance	of	these	findings,	and	of	the	putative	role	
of	serotonin	for	the	anxiogenic	effects	of	self-administered	cocaine,	are	provided	in	
the	final	Chapter	of	this	document.	What	follows	below	is	a	summary	of	the	
behavioral	effects	observed	in	cocaine-seeking	animals	treated	with	intra-BNST	CP	
94,243	and	the	conclusions	stemming	from	those	results.	
• Start	latencies	decreased	over	the	course	of	trials	for	all	groups	of	animals,	
irrespective	of	treatment,	indicating	that	activation	of	5-HT1B	auto-receptors	in	
the	BNST	did	not	affect	the	animals’	motivation	to	seek	1.0	mg/kg	i.v.	cocaine.	
This	result	is	consistent	with	previous	reports	from	our	laboratory	that	
antagonism	of	5-HT	cell	function	within	the	DRN	similarly	did	not	alter	the	start	
latencies	of	rats	running	an	alley	for	cocaine	(Ettenberg	et	al.,	2011)	and	that	
systemic	administration	of	a	5-HT	antagonist	did	not	alter	the	conditioned	place	
preferences	produced	by	pairing	a	novel	environment	with	the	immediate	
effects	of	i.v.	cocaine	(Ettenberg	&	Bernardi,	2007).	
• Also	as	previously	reported	(see	review	by	Ettenberg,	2004),	Run	Times	
increased	over	the	course	of	testing	in	cocaine-reinforced	animals	treated	with	
i.c.	vehicle.	This	effect	was	significantly	reversed	by	intra-BNST	application	of	CP	
94,243,	suggesting	that	activation	of	5-HT1B	receptors	in	the	BNST	rendered	the	
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animals	less	ambivalent	about	entering	the	cocaine-associated	goal	box	
compared	to	vehicle-treated	animals.		
• The	hypothesis	that	the	changes	in	Run	Time	reflect	reductions	in	ambivalence	
about	goal-box	entry	is	supported	by	the	observation	that	CP	94,253	infused	into	
the	BNST	also	produced	significant	reductions	in	the	frequency	of	approach-
avoidance	retreat	behaviors.		
• These	effects	of	intra-BNST	CP	94,253	cannot	be	easily	accounted	for	by	a	
general	reduction	in	anxiety	produced	by	the	pretreatment	prior	to	runway	
testing,	since	post-treatment	(5	mins	after	cocaine	infusion)	with	CP	94,253	was	
also	effective	at	reducing	retreat	behaviors	even	when	the	animals	were	tested	
in	an	undrugged	state.		
• Additionally,	the	reductions	in	retreat	frequency	and	faster	Run	Times	produced	
by	intra-BNST	CP	94,253	cannot	be	accounted	for	by	a	nonspecific	change	in	the	
subjects’	level	of	arousal	or	activity	since	the	treatments	did	not	produce	
significant	alterations	in	locomotor	activity.	
• The	specificity	of	the	observed	effects	to	the	5-HT1B	receptor,	was	confirmed	by	
the	observation	that	the	behavioral	actions	of	the	agonist	were	reversed	by	co-
administration	with	the	selective	5-HT1B	antagonist	NAS-181.	
• Given	the	known	high	density	of	5-HT1B	receptors	on	serotonergic	terminals	
within	the	BNST(Hazra	et	al.,	2012)	it	is	hypothesized	that	the	current	results	are	
attributable	to	a	reduction	in	5-HT	release	within	the	BNST.		
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• On	that	basis,	one	can	conclude	that	the	changes	in	runway	behavior	observed	in	
treated	animals	are	consistent	with	the	hypothesis	that	5-HT	innervation	of	the	
BNST	contributes	to	the	anxiogenic	response	to	cocaine.			
• Chapter	4,	which	follows	below,	describes	experiments	comparable	to	those	
described	here	but	focused	instead	on	the	LHb	by	examining	the	impact	of	intra-
habenular	CP	94,243	on	the	behavior	of	animals	seeking	cocaine	in	the	runway.		
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Chapter	4:	Cocaine,	Serotonin,	and	the	Lateral	Hanenula	(LHb)	
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4.1	Introduction	
The	set	of	experiments	described	in	this	chapter	reflect	the	same	approach	
as	that	described	in	the	previous	chapter	for	the	study	of	how	5-HT	release	in	the	
BNST	affects	the	anxiogenic	response	to	cocaine	–	with	the	exception	that	the	brain	
target	now	is	the	lateral	habenula	(Hb).	As	discussed	in	Chapter	1,	the	Lateral	
Habenula	(LHb)	has	been	implicated	in	the	modulation	of	both	rewarding	and	
aversive	states	(Lecca,	Meye,	&	Mameli,	2014;	Meye,	Lecca,	Valentinova,	&	Mameli,	
2013;	Velasquez	et	al.,	2014).	Electrophysiological	studies	of	the	LHb	suggest	a	role	
for	this	region	in	preventing	or	blocking	the	behavioral	impact	of	rewarding	stimuli	
via	an	inhibition	of	midbrain	substantia	nigra	dopamine	(DA)	“reward”	neurons	
(Matsumoto	&	Hikosaka,	2007,	2009).	Indeed,	studies	of	both	human	(Shepard	et	al.,	
2006;	Ullsperger	&	Cramon,	2003)	and	animal	subjects	(e.g.,	Ootsuka	&	Mohammed,	
2015;	Tomaiuolo	et	al.,	2014),	indicate	that	the	LHb	is	activated	by	the	presentation	
of	aversive	stimuli,	including	the	administration	of	cocaine	(Gill	et	al.,	2013;	Jhou	et	
al.,	2013).	The	putative	importance	of	5-HT	in	the	functional	role	of	the	LHb	is	
suggested	by	the	fact	that	it	has	prominent	reciprocal	projections	to	both	the	dorsal	
(DRN)	and	median	(MRN)	raphé	nuclei	of	the	brainstem	(Lidov	&	Molliver,	1982;	Luo	
et	al.,	2015;	Metzger	et	al.,	2017)	and	that	it	expresses	a	whole	host	of	5-HT	
receptors,	including	the	5-HT1,	5-HT2,	5-HT3,	5-HT5,	and	5-HT7	families	(Metzger	et	
al.,	2017).	Of	particular	interest	to	the	current	study	is	the	presence	of	inhibitory	5-
HT1B	receptors	in	the	LHb	(Tchenio	et	al.,	2016;	Wagner,	Bernard,	et	al.,	2016;	
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Wagner,	French,	et	al.,	2016).		As	described	in	Chapter	1,	the	5-HT1B	receptor	is	an	
inhibitory	Gi-coupled	receptor	that	is	primarily	located	on	axon	terminals	as	an	auto-	
or	hetero-receptor	(Boschert	et	al.,	1994).	Additionally,	systemic	treatment	with	5-
HT1B	agonists	has	been	shown	to	produce	anxiolytic-like	effects	across	multiple	
behavioral	tests	(Chojnacka-Wojcik	et	al.,	2005;	Tatarczynska,	2004),	which	further	
supports	the	hypothesis	that	this	receptor	may	be	involved	in	modulating	the	
anxiogenic	response	to	cocaine.	Thus,	the	present	study	was	designed	to	investigate	
the	role	of	5-HT	signaling	in	the	LHb	(via	manipulation	of	5-HT1B	receptors)	on	the	
development	of	the	anxiogenic	effects	of	cocaine	as	measured	in	the	drug	self-
administration	runway.	
4.2	Materials	and	Methods	
4.2.1	Subjects	
Subjects	were	122	Male	Sprague-Dawley	rats,	with	housing	and	living	
conditions	as	described	in	Chapter	2	above.	
4.2.2	Surgery	
	 Surgical	procedures	were	performed	as	described	in	Chapter	2.	Briefly,	rats	
were	fitted	with	an	i.v.	jugular	catheter	and	implanted	with	bilateral	cannula	aimed	
2.0	mm	above	the	LHb.	
4.2.3	Drugs	
Cocaine	hydrochloride	and	the	5-HT1B	agonist	CP	94,253	dihydrochloride	
were	prepared	as	previously	described.	Once	again,	to	demonstrate	specificity	to	the	
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5-HT1B	receptor,	the	antagonist	NAS-181	was	employed	to	reverse	any	observed	
behavioral	effects	obtained	with	the	5-HT1B	agonist.		
4.2.4	Procedures	
After	a	single	10	min	habitation	trial,	the	first	of	16	consecutive	one-trial-per-
day	runway	trials	was	initiated	(see	Fig	2.2	for	the	experimental	timeline).	Prior	to	
each	trial,	the	subjects	were	administered	bilateral	intra-LHb	infusions	(0.5	μl/side)	
of	one	of	two	doses	of	CP	94,253	(0.1	or	0.25	μg/side	(in	Experiment	IV),	or	the	
combination	of	0.25µg	CP	94,253	with	0.1	µg	NAS-181	per	side	(Experiment	V),	or	
vehicle	prior	to	each	runway	trial.	After	10	min,	each	subject	was	moved	to	the	
runway	apparatus,	connected	to	the	i.v.	drug	delivery	system,	and	tested	for	their	
motivation	to	seek	cocaine.	Once	again,	all	trials	for	a	given	subject	were	conducted	
in	the	same	apparatus	and	catheter	patency	was	maintained	by	flushing	the	
catheters	daily	with	0.1	ml	of	cefazolin/gentamycin	followed	by	0.1	ml	heparinized	
saline	after	removal	from	the	apparatus.	
4.3	Results	
4.3.1	Histology	
	 Figure	4.1	shows	the	placement	of	bilateral	cannula	tips	located	in	the	
targeted	region	(figure	adapted	from	the	brain	atlas	of	Paxinos	&	Watson,	2005).	
Inclusion	of	subjects	in	the	experiment	required	strict	histological	confirmation	that	
both	cannula	tips	were	accurately	localized	to	the	LHb.	Any	animal	with	
microinjector	tips	located	outside	the	target	region	or	displaying	significant	necrosis	
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around	injector	tips	was	removed	from	the	study	(n=23).	The	final	histological	
determination	of	a	subject’s	inclusion	in	the	study	was	made	by	a	trained	individual	
blind	to	that	animal’s	treatment	group.	An	additional	30	animals	failed	to	maintain	
catheter	patency	throughout	the	duration	of	the	study	and	were	similarly	removed	
from	the	data	analysis	resulting	in	a	final	total	sample	size	of	69	subjects	for	data	
analysis.		
4.3.2	Experiment	IV:	Intra-LHb	Infusion	of	CP	94,253		
This	experiment	tested	the	effects	of	bilateral	intra-LHb	microinjections	of	CP	
94,253	(0,	0.1,	or	0.25	µg/0.5	µl/side)	on	the	runway	behavior	of	animals	
approaching	and	entering	a	goal	box	associated	with	the	administration	of	1.0	mg/kg	
i.v.	cocaine.	Group	sizes	were	n	=	22,	13,	18,	respectively.	Figure	4.2	depicts	the	
mean	(±SEM)	runway	performance	of	the	3	groups	of	animals	during	the	16	days	of	
runway	testing.	A	two-factor	(Group	x	Trials)	Analysis	of	Variance	(ANOVA)	
conducted	on	the	start	latency	data	revealed	a	significant	main	effect	of	Trial	
F(15,750)=6.822,	p	<	.001,	but	no	main	effect	of	Group	and	no	Group	x	Trial	
interaction	(p’s	>	.05).	Thus,	all	animals,	irrespective	of	group,	learned	the	
association	between	the	goal	box	and	drug	delivery	and	displayed	an	increasing	
motivation	to	seek	the	drug	(faster	start	times)	as	testing	progressed.		
		 	
	 68	
	
	
Figure	4.1	Histological	confirmation	of	cannula	placements	in	the	LHb	
Shaded	areas	indicate	regions	where	successful	cannula	tip	placements	could	be	
verified.	Numbers	represent	distance	of	coronal	slices	posterior	to	bregma.	Due	to	
the	volume	of	drug	injected	(0.5	µl/side)	and	the	target	region’s	proximity	to	the	
midline,	the	area	affected	likely	includes	a	broad	region	of	both	the	lateral	habenula	
(LHb)	and	medial	habenula	(MHb).	Figure	adapted	from	Paxinos	&	Watson	(2007).	
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Despite	the	fast	start	latencies,	animals	took	longer	and	longer	to	enter	the	goal	box	
over	trials.	Another	two-factor	(Group	x	Trial)	ANOVA	computed	on	the	run	time	
data	confirmed	a	significant	main	effect	of	Trial	(F(15,750)=2.876,	p	<	.001)	but	in	
the	opposite	direction	of	start	times	(i.e.,	longer	latencies;	see	middle	panel	of	
Figure	4.2).	While	there	was	no	main	effect	of	Group	(F(2,50)=2.298,	p	=	.111),	there	
was	a	statistically	significant	Group	x	Trial	interaction	(F(30,750)=1.641,	p	=	.017),	
reflecting	the	fact	that	on	the	early	trials	of	testing	the	Groups	performed	
comparably	while	by	the	end	of	testing	the	run	times	of	the	three	groups	diverged.	A	
series	of	pairwise	comparisons	computed	on	these	data	revealed	a	significant	group	
difference	between	animals	treated	with	vehicle	versus	the	0.25µg	dose	(p	=	.038).	
To	confirm	this	assessment,	the	mean	Run	Times	for	the	three	groups	were	
recomputed	by	averaging	performance	during	the	first	8	trials	to	that	observed	
during	the	final	8	trials	(as	described	and	illustrated	in	Chapter	3).	Those	results	are	
depicted	in	Figure	4.3A.	A	two-factor	(Group	x	Trials)	ANOVA	computed	on	these	
data	produced	results	consistent	with	the	ANOVA	computed	on	all	trials.	There	was	
no	main	effect	of	Trials	(F(1,50)=0.185,	p	=	.669),	or	Group	(F(2,50)=2.298,	p	=	.111),	
however	there	was	a	significant	Group	X	Trials	interaction	(F(2,50)=3.982,	p=	.025).	
To	elucidate	the	source	of	this	interaction,	a	one-way	ANOVA	was	computed	on	the	
data	for	each	set	of	trials,	which	revealed	no	group	differences	during	trials	1-8	
(F(2,52)=0.373,	p	=	.691),	but	a	significant	effect	of	Group	during	trials	9-16		
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Figure	4.2	
Group	Mean	(±SEM)	start	latencies	(top	panel),	run	times	(middle	panel),	and	
approach-avoidance	retreat	behavior	(bottom	panel)	of	animals	running	a	straight	
alley	once	daily	for	an	infusion	of	1.0	mg/kg	i.v.	cocaine	after	pretreatment	with	
either	0.1	(dotted	lines)	or	0.25	µg	(dashed	lines)	CP	94,253,	or	vehicle	(solid	lines)	
into	the	LHb.	
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Figure	4.3	Top	Panel	(A):	Group	Mean	(±SEM)	Total	Run	Times	averaged	over	the	
first	half	(left)	of	trials	and	the	last	half	(right)	for	animals	treated	with	bilateral	
infusions	of	vehicle	(Veh),	0.1	µg	or	0.25	µg	of	CP	94,253	into	the	LHb.	Bottom	Panel	
(B):	Group	Mean	(±SEM)	retreat	frequency	summed	over	the	first	half	and	the	last	
half	of	runway	trials.	*(p	<	.05)	when	compared	to	vehicle		
	
	
	 72	
(F(2,52)=4.778,	p	=	.013).	Post	hoc	analysis	by	LSD	testing	showed	that	the	0.25	µg	
dose	was	significantly	different	than	vehicle-treated	animals	(p	=	.003).	
The	increase	in	Run	Times	observed	as	testing	progressed	was	mirrored	by	
the	frequency	of	approach-avoidance	retreat	behaviors	(see	Figures	4.2	and	4.3B).	
Not	surprisingly,	an	animal	that	stops	and	retreats	back	toward	the	start	box	will	
necessarily	delay	its	entry	into	the	goal	box.	This	was	confirmed	via	Pearson	
correlational	analyses,	whereby	each	animal’s	run	time	was	correlated	with	the	
frequency	of	approach-avoidance	retreats	during	each	of	the	16	days	of	testing.	
Unsurprisingly,	the	correlation	between	run	times	and	retreats	was	statistically	
significant	on	all	16	days	of	testing	(Table	4.1).		
A	two-factor	(Group	x	Trials)	ANOVA	was	computed	on	the	approach-
avoidance	retreat	data	(Figure	4.2,	bottom	panel),	which	revealed	a	significant	main	
effect	of	Trials	(F(15,750)=8.865,	p	<	.001),	but	no	effect	of	Group	(F(2,50)=1.909,	p	=	
.159),	and	only	a	marginal	Group	x	Trials	interaction	(F(30,750)=1.404,	p	=	.075).	
However,	as	was	done	for	the	run	time	analysis,	the	data	were	analyzed	by	
comparing	performance	over	the	first	half	of	trials	versus	the	last	half	of	trials.	The	
results	were	comparable	to	those	observed	for	run	times.	A	two-factor	(Group	X	
Trials)	ANOVA	was	computed	on	the	data	collapsed	across	trials.	This	analysis	
revealed	a	significant	main	effect	of	Trials	(F(1,50)=30.742,	p	<	.001),	no	main	effect	
of	Group	(F(2,50)=1.909,	p	=	.159),	and	a	significant	Group	x	Trials	interaction	
(F(2,50)=4.891,	p	=	.011).	
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Table	4.1.	Correlations	between	Total	Run	Time	and	Retreat	Frequency	across	
trials	
Trial	 Pearson	R=	 P	-	Value	
1	 .442	 .001	
2	 .392	 .004	
3	 .614	 <.001	
4	 .716	 <.001	
5	 .608	 <.001	
6	 .728	 <.001	
7	 .620	 <.001	
8	 .558	 <.001	
9	 .638	 <.001	
10	 .725	 <.001	
11	 .732	 <.001	
12	 .770	 <.001	
13	 .775	 <.001	
14	 .788	 <.001	
15	 .694	 <.001	
16	 .750	 <.001	
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As	was	the	case	for	Run	Times,	a	one-way	ANOVA	comparing	group	behavior	
over	the	first	half	of	trials	produced	no	reliable	differences	(F(2,52)=.233,	p	=	.793),	
while	a	significant	group	effect	was	identified	during	the	second	half	of	runway	trials	
(F(2,52)=3.260,	p	=	.047).	Post	hoc	analysis	via	LSD	testing	showed	a	significant	
difference	between	the	0.25	µg	dose	group	and	vehicle	(p	=	.014).	Indeed,	as	Fig	
4.3B	illustrates,	while	retreats	increased	during	the	second	half	of	the	experiment	in	
the	vehicle	group	(as	we	have	seen	previously;	e.g.	see	review	by	Ettenberg,	2004),	
intra-LHb	pretreatment	with	the	5-HT1B	agonist	CP	94,253	dose-dependently	
reversed	this	effect.	
4.3.3	Experiment	V:	Co-administration	of	5-HT1B	agonist	and	antagonist	
To	demonstrate	specificity	to	the	5-HT1B	receptor	subtype,	the	effective	dose	
of	0.25	µg	CP	94,253	was	challenged	by	co-administration	of	the	selective	5-HT1B	
receptor	antagonist,	NAS-181	(0.1	µg/side;	n=16).	NAS-181	was	effective	at	
reversing	the	effect	of	the	agonist	on	approach-avoidance	retreat	behavior	when	co-
administered	with	0.25	µg	of	CP-	94,253	(Figure	4.4).	As	in	the	previous	experiment,	
data	for	this	group	was	collapsed	into	the	first	half	and	second	half	of	runway	trials,	
and	then	analyzed	by	a	paired	sample	two-tailed	t-test,	which	revealed	a	significant	
difference	in	retreat	behavior	over	the	course	of	trials	(t(15)=-2.503,	p	=	.024).	
Indeed,	these	animals	behaved	much	like	the	vehicle-treated	subjects	in	Experiment	
IV	(Fig	4.3B)	and	increased	the	number	of	retreats	as	testing	progressed.	A	direct	
comparison	between	the	retreat	behavior	of	Vehicle-treated	animals	from	
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Experiment	IV	on	Trials	9-16	and	the	animals	in	Experiment	V	from	the	same	time	
period	showed	no	differences	between	the	groups	(t(36)=1.207,	p	=	.235).		The	
antagonist,	therefore,	reversed	the	retreat-suppressing	effects	of	the	5-HT1B	agonist	
alone.		
4.3.4	Locomotor	Activity	Test	
The	effects	of	CP	94,253	on	spontaneous	locomotor	activity	was	assessed	by	
a	two-factor	(Group	x	Time)	ANOVA	computed	on	data	acquired	for	15	mins	
following	drug	infusion	(depicted	in	Figure	4.5).	Although	there	was	an	expected	
reduction	in	locomotor	activity	over	time	as	animals	habituated	to	the	apparatus	
(significant	main	effect	of	Time:	F(2,86)=165.85,	p	<	.001),	there	was	no	main	effect	
of	Group(F(2,43)=1.315,	p	=	.279)	and	no	Group	x	Time	interaction	(F(4,86)=.442,	p	=	
.778).	Thus,	manipulation	of	the	5-HT1B	receptor	in	the	LHb	produced	no	perceptible	
alterations	in	the	spontaneous	ambulatory	behavior	of	subjects	relative	to	vehicle	
control.	Additionally,	in	a	subsequent	locomotor	test	of	animals	from	Experiment	V,	
treatment	with	CP	94,253	+	NAS-181	produced	no	reliable	changes	(compared	to	the	
agonist	alone)	in	locomotor	behavior	(data	not	shown).	
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Figure	4.4	CP	94,253	+	NAS-181	in	the	LHb	
Group	Mean	(±SEM)	retreat	frequency	was	summed	over	the	first	half	(left)	of	trials	
and	the	last	half	(right)	for	the	n=16	animals	who	received	the	combined	infusion	of	
0.25	µg	CP	94,253	and	0.1	µg	NAS-181	prior	to	runway	testing.	*	p<.05		
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Figure	4.5	Spontaneous	locomotor	activity	
Group	Mean	(±SEM)	spontaneous	locomotor	activity	immediately	after	infusion	of	
CP	94,253.	The	total	distance	traveled	(cm)	was	recorded	over	5-min	intervals	for	a	
15-min	test	session.		
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4.4	Conclusions	
	
• As	described	in	Chapter	3,	start	latencies	were	found	to	decrease	as	runway	
testing	progressed	for	all	groups	of	animals	indicating	that,	as	was	the	case	
for	intra-BNST	manipulations,	activation	of	5-HT1B	receptors	within	the	LHb	
did	not	affect	animals’	motivation	to	seek	1.0	mg/kg	i.v.	cocaine.	The	positive	
incentive	properties	of	cocaine	appear	to	have	been	unaffected	by	intra-LHb	
administration	of	CP	94,253.	
• While	vehicle-treated	animals	working	for	cocaine	exhibited	the	typical	
increase	in	run	times	over	trials,	intra-LHb	CP	94,253	produced	a	dose-
dependent	reduction	in	this	effect.		
• CP	94,253	was	also	observed	to	produce	dose-dependent	reductions	in	the	
frequency	of	approach-avoidance	retreat	behaviors	as	animals	ran	the	
alleyway	for	cocaine.		
• The	changes	observed	in	run	times	(time	to	enter	the	goal	box)	would,	of	
course,	be	expected	to	increase	as	animals	exhibit	changes	in	the	frequency	
of	approach-avoidance	retreat	behaviors	–	i.e.,	it	should	take	longer	to	enter	
the	goal	box	if	the	subject	is	making	increasing	numbers	of	approach-
avoidance	responses.	This	was	confirmed	by	the	demonstration	of	strong	and	
highly	significant	correlations	between	the	run	times	and	retreat	frequencies	
across	all	animals	in	all	groups.			
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• As	was	the	case	for	intra-BNST	applications	of	CP	94,253,	intra-LHb	infusion	
of	the	5-HT1B	agonist	did	not	produce	significant	alterations	in	spontaneous	
locomotor	activity	which	could	otherwise	have	accounted	for	the	observed	
differences	in	runway	behavior.	
• Finally,	the	specificity	of	CP	94,253’s	agonist	effects	at	the	5-HT1B	receptor	
was	confirmed	by	the	observation	that	the	agonist’s	behavioral	effects	were	
reversed	by	co-administration	of	the	selective	5-HT1B	antagonist	NAS-181.	
• It	would	seem	then	that	serotonergic	innervation	of	both	the	lateral	
habenula	(this	Chapter)	and	the	BNST	(Chapter	3)	can	contribute	to	or	
modulate	the	anxiogenic/aversive	response	to	self-administered	cocaine.	
• This	hypothesis	was	further	tested	in	the	experiments	described	in	Chapter	5,	
which	examined	the	impact	of	selective	lesions	of	the	5-HT	terminals	within	
the	BNST	and	LHb.	
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Chapter	5:	Effects	of	selective	lesions	of	5-HT	terminals	within	the	BNST	&	LHb	on	
the	runway	behavior	of	rats	working	for	cocaine	
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5.1	Introduction	
The	previous	chapters	described	experiments	that	all	used	the	same	method	
of	pharmacological	inhibition	of	serotonergic	synapses	via	activation	of	5-HT1B	
autoreceptors.	While	this	method	is	useful,	it	does	have	some	disadvantages,	
including:	the	necessity	of	repeated	intracranial	infusions,	the	handling	stress	
associated	with	the	aforementioned	infusions,	potential	for	infection	or	tissue	
necrosis	from	repeated	cerebral	trauma,	as	well	as	the	potential	for	off-target	
effects	mediated	by	5-HT1B	receptors	on	other,	non-serotonergic	synapses	in	the	
regions	of	interest.	To	address	those	issues,	the	use	of	a	selective	serotonergic	
neurotoxin	was	used	in	the	experiments	described	herein.	This	neurotoxin	is	a	drug	
called	5,7-Dihydroxytryptamine,	which	works	by	entering	serotonergic	terminals	via	
SERT,	and	through	the	production	of	oxidative	free	radicals	causes	denervation	of	
the	affected	region	(Baumgarten,	Klemm,	Sievers,	&	Schlossberger,	1982;	Daly,	Fuxe,	
&	Jonsson,	1974).	It	is	potent	enough	to	effectively	eliminate	the	brain	of	serotonin	
from	selective	brain	targets	(Fuxe	&	Jonsson,	1974).	For	this	reason,	it	has	become	
an	important	tool	to	study	the	behavioral	effects	mediated	by	brain	5-HT	systems.	
For	example,	it	has	been	used	to	assess	the	role	of	5-HT	in	conditioned	reward	
(Fletcher	et	al.,	1999),	the	processing	of	irrelevant	stimuli	in	the	NAcc	(Nelson	et	al.,	
2012),	and	the	anxiogenic	response	of	animals	to	aversive	stimuli	or	environments	
(Sziray,	Kuki,	Nagy,	Markó,	Kompagne,	&	Lévay,	2010).	It	has	also	been	used	to	
disrupt	fear	conditioning	and	anxiety	through	5-HT	depletion	in	the	basolateral	
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amygdala	(Johnson,	Molosh,	Fitz,	Arendt,	Deehan,	Federici,	Bernabe,	Engleman,	
Rodd,	Lowry,	&	Shekhar,	2015).	In	the	present	set	of	experiments,	the	effects	of	5,7-
DHT-induced	lesions	of	5-Ht	terminals	in	the	BNST	and	LHb	were	examined	on	the	
runway	behavior	of	animals	working	for	i.v.	cocaine.		
5.2	Materials	and	Methods	
5.2.1	Subjects	
	 Subjects	were	85	Male	Sprague-Dawley	rats,	with	housing	and	living	
conditions	as	described	in	Chapter	2	above.	
5.2.2	Surgery	
	 Surgical	procedures	were	performed	as	outlined	in	Chapter	2.	Rats	were	each	
fitted	with	an	intravenous	jugular	catheter	while	still	under	deep	anesthesia.	During	
the	same	surgery,	each	animal	received	bilateral	microinjections	of	either	8.0	µg/1.0	
µl	5,7-DHT	or	vehicle	(0.2%	Ascorbic	acid	in	0.9%	physiological	saline).	Each	infusion	
was	performed	slowly,	at	a	rate	of	200	µl/min	for	5	mins,	after	which	the	infusion	
cannula	was	left	in	place	for	an	additional	2	mins	to	allow	the	drug	to	diffuse	into	
the	target	areas	and	away	from	the	cannula	tip.	To	prevent	damage	to	NE	terminals	
in	the	target	areas,	30	mins	before	the	5-HT	neurotoxin	applications	each	animal	
was	treated	with	25	mg/kg	desipramine	(Sigma-Aldrich)	i.p.	(Nelson	et	al.,	2012;	
Sziray	et	al.,	2010).	The	coordinates	employed	for	the	stereotaxic	application	of	the	
neurotoxin	were	aimed	directly	into	the	BNST	or	LHb	(not	above	the	targets,	as	in	
the	previous	experiments).		The	coordinates,	relative	to	bregma	were:	for	the	BNST,	
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AP	−0.4,	ML	±3.5,	and	DV	−6.4	from	skull	surface	with	a	lateral	inclination	of	15°,	and	
for	the	LHb,	AP	−3.4,	ML	±1.5,	and	DV	−3.4		from	skull	surface	with	a	lateral	
inclination	of	11°	(Paxinos	&	Watson,	2007).		
5.2.3	Drugs	
As	described	in	chapter	2,	cocaine	hydrochloride	served	as	the	drug	
reinforcer	in	the	runway	studies	and	was	again	infused	i.v.	in	the	goal	box	at	a	dose	
of	1.0	mg/kg/infusion.	The	selective	serotonergic	neurotoxin,	5,7-
Dihydroxytryptamine	(5,7-DHT)	was	prepared	in	a	vehicle	of	0.2%	ascorbic	acid	and	a	
concentration	of	8.0	µg/µl.	The	NE	reuptake	inhibitor	drug	desipramine	was	
prepared	at	a	concentration	of	25	mg/ml	in	0.9%	physiological	saline	for	IP	injection	
at	a	dose	of	25	mg/kg.		
5.2.4	Procedures	
Behavioral	testing	began	one	week	after	surgery	and	conducted	as	previously	
described	–	one	day	of	habituation	to	the	apparatus,	followed	by	16	days	of	single-
trials	in	the	drug	self-administration	runway.	Since	the	experimental	manipulation	in	
the	experiments	involved	the	application	of	the	neurotoxin	during	surgery,	there	
were	no	pretreatments	prior	to	runway	testing.	Animals	were	removed	from	their	
home	cage,	each	day	brought	to	the	runway	apparatus,	connected	to	the	i.v.	drug	
delivery	system,	and	placed	into	the	start	box	where,	after	5	s,	the	start	door	was	
opened	and	the	trial	initiated.	Upon	entering	the	goal	box,	the	goal	door	
automatically	closed	behind	the	subject	(to	prevent	retracing)	and	an	i.v.	infusion	of	
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cocaine	was	administered.	After	5	min,	the	subjects	were	removed	from	the	goal	
box,	disconnected	from	the	drug	delivery	system,	and	returned	to	their	home	cages.	
As	previously	stated,	catheter	patency	was	maintained	by	daily	i.v.	“flushing”	of	the	
catheter	with	0.1	ml	of	cefazolin/gentamycin	followed	by	0.1	ml	heparinized	saline.		
	 As	in	previous	chapters,	after	runway	testing	was	complete,	animals	
underwent	a	behavioral	assay	for	non-specific	motoric	effects	of	the	treatment.	
Since	these	animals	had	chronic	lesions,	no	baseline	tests	were	conducted,	and	a	
between-group	analysis	used	to	detect	differences	in	locomotor	activity	between	
the	treatment	groups.	Subjects	underwent	a	30	min	testing	session	during	which	
time	the	total	distance	traveled	(cm)	was	measured	in	5	min	intervals.	
5.2.5	Histology	
	 After	the	conclusion	of	behavioral	testing,	animals	were	euthanized	with	an	
overdose	of	sodium	pentobarbital	and	received	transcardiac	perfusions	of	120ml	
PBS	followed	by	120ml	4%	PFA.	Brain	tissue	was	post	fixed	overnight	in	4%	PFA	at	
4˚C	before	being	transferred	to	30%	sucrose	for	cryoprotection.	Tissue	was	sliced	to	
a	thickness	of	40	µm	on	a	freezing	microtome	and	sections	containing	either	the	LHb	
or	BNST	(Experiments	VI	and	VII,	respectively)	were	stained	using	
immunohistochemistry	to	visual	serotonergic	fibers.	Antibodies	against	5-HT	(Rabbit	
anti-5-HT,	Immunostar)	itself	as	well	as	SERT	(rabbit	anti-SERT,	Immunostar),	the	
serotonin	transporter,	were	both	tested.	The	signal	was	then	amplified	using	a	
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biotinylated	donkey	anti-rabbit	secondary	antibody,	and	the	slides	developed	with	
the	ABC	reagent	kit	(Vectastain)	and	DAB.	
5.3	Results	
5.3.1.	Histology	
	 A	number	of	complications	arose	during	the	immunohistochemistry	staining	
procedure	which	caused	this	procedure	to	fail.	Initial	tests	with	both	5-HT	and	SERT	
antibodies	showed	some	staining	of	5-HT	fibers,	but	with	an	excessive	background	
signal.	Multiple	subsequent	runs	of	the	procedure	necessitated	the	use	of	significant	
amounts	of	brain	tissue.	Additionally,	the	hurdles	encountered	during	these	tests	
caused	significant	delays	in	processing	the	tissue,	which	resulted	in	the	loss	of	a	
number	of	samples	due	to	mold	growth.	For	these	reasons,	neither	the	efficacy	of	
the	lesion,	nor	the	extent	of	affected	tissue	could	be	verified.		
5.3.2	Experiment	VI:	5,7-DHT	lesion	of	the	LHb	
This	experiment	tested	the	effects	of	bilateral	intra-LHb	microinjections	of	
5,7-DHT	(8.0	µg/µl/side)	or	vehicle	on	the	runway	behavior	of	animals	approaching	
and	entering	a	goal	box	associated	with	the	administration	of	1.0	mg/kg	i.v.	cocaine.	
Group	sizes	were	n	=	19	for	the	vehicle	group	and	n	=	21	for	the	5,7-DHT	lesion	
group.	Figure	5.1	depicts	the	mean	(±SEM)	runway	performance	of	both	groups	of	
animals	during	the	16	days	of	runway	testing.	A	two-factor	(Group	x	Trials)	Analysis	
of	Variance	(ANOVA)	conducted	on	the	start	latency	data	(Figure	5.1,	Top	panel)	
revealed	a	significant	main	effect	of	Trials	(F(15,570)=3.221,	p	<	.001),	but	no	main	
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effect	of	Group	(F(1,38)=.377,	p	=	.543)	and	no	Group	x	Trial	interaction	
(F(15,570)=1.009,	p	=	.444).	Thus,	all	animals,	irrespective	of	group,	learned	the	
association	between	the	goal	box	and	drug	delivery	and	displayed	an	increasing	
motivation	to	seek	the	drug	(faster	start	times)	as	testing	progressed.	However,	
despite	the	fast	start	latencies,	animals	took	longer	and	longer	to	enter	the	goal	box.	
Another	two-factor	(Group	x	Trial)	ANOVA	computed	on	the	run	time	data	(Figure	
5.1,	Middle)	confirmed	a	significant	main	effect	of	Trial	(F(15,570)=5.612,	p	<	.001)	
but	in	the	opposite	direction	of	start	times	(see	middle	panel	of	Figure	5.2).	While	
the	figure	suggests	the	possibility	that	the	5-HT-LHb	lesioned	animals	were	slower	to	
enter	the	goal	box,	this	effect	was	not	statistically	significant;	i.e.,	there	was	no	main	
effect	of	Group	(F(1,38)=.897,	p	=	.349),	nor	a	statistically	significant	Group	x	Trial	
interaction	(F(15,570)=1.039,	p	=	.413).	Analysis	of	approach-avoidance	retreat	
behavior	(Figure	5.1,	Bottom	panel)	similarly	revealed	a	significant	main	effect	of	
Trials	(F(15,570)=13.558,	p	<	.001)	(when	averaged	across	all	animals),	subjects	
tended	to	make	more	retreats	as	testing	progressed),	but	no	main	effect	of	Group	
(F(1,38)=1.130,	p	=	.295),	nor	a	Group	x	Trials	interaction	(F(15,570)=1.154,	p	=	.304).	
As	was	the	case	for	run	time,	the	retreat	frequency	data	were	suggestive	of	an	
increased	number	of	approach-avoidance	retreats	in	the	lesioned	group	relative	to	
the	vehicle	controls,	but	the	results	were	clearly	not-significant	and,	if	anything,	
were	directionally	opposite	in	direction	to	the	predicted/hypothesized	outcome.			
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Figure	5.1	Group	Mean	(±SEM)	start	latencies	(top	panel),	run	times	(middle	panel),	
and	approach-avoidance	retreat	behavior	(bottom	panel)	of	animals	running	a	
straight	alley	once	daily	for	an	infusion	of	1.0	mg/kg	i.v.	cocaine	after	treatment	with	
either	8.0	µg	5,7-DHT	(dashed	lines)	or	vehicle	(dotted	lines)	into	the	LHb.		
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5.3.3	Experiment	VII:	5,7-DHT	Lesion	of	the	BNST	
This	experiment	was	conducted	in	an	identical	manner	to	Experiment	I,	
above,	but	this	time	the	5-HT	lesions	were	targeted	at	the	BNST.	Animals	received	
either	5,7-DHT	(8.0	µg/µl/side)	or	vehicle,	n	=	5	per	group,	and	were	subsequently	
tested	in	the	runway	apparatus	to	assess	the	development	of	approach-avoidance	
retreat	behaviors	in	response	to	1.0	mg/kg	i.v.	cocaine.	Figure	5.2	depicts	the	mean	
(±SEM)	group	performance	during	runway	testing.		A	two-factor	(Group	x	Trials)	
Analysis	of	Variance	(ANOVA)	conducted	on	the	start	latency	data	(Figure	5.2,	Top	
panel)	failed	to	show	an	effect	of	Trials	(F(15,120)=1.404,	p	=	.156),	or	Group	
F(1,8)=.022,	p	=	.887),	or	the	Group	x	Trial	interaction	(F(15,120)=.659,	p	=	.820).	
While	there	were	clearly	no	group	differences	in	start	latency,	it	was	surprising	that	
the	reductions	observed	over	trials	did	not	reach	statistical	significance	as	both	
groups	left	the	start	box	faster	by	the	end	of	testing	than	they	did	at	the	outset.	A	
paired-samples	t-test	comparing	the	start	latencies	on	Day	1	of	testing	with	those	on	
Day	16	just	barely	reached	statistical	significance	(t(9)=2.920,	p	=	.048),	indicating	
that	the	animals	did	indeed	show	an	increased	motivation	to	seek	cocaine	over	the	
course	of	testing.	High	within-group	variability	and	small	sample	sizes	may	have	
resulted	in	inadequate	power	to	observe	a	statistically	reliable	effect	in	the	ANOVA.		
Despite	relatively	fast	start	latencies,	animals	took	longer	and	longer	to	enter	
the	goal	box.	Another	two-factor	(Group	x	Trial)	ANOVA	computed	on	the	run	time		
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Figure	5.2	Group	Mean	(±SEM)	start	latencies	(top	panel),	run	times	(middle	panel),	
and	approach-avoidance	retreat	behavior	(bottom	panel)	of	animals	running	a	
straight	alley	once	daily	for	an	infusion	of	1.0	mg/kg	i.v.	cocaine	after	treatment	with	
either	8.0	µg	5,7-DHT	(dashed	lines)	or	vehicle	(dotted	lines)	into	the	BNST.	
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data	(Figure	5.2,	Middle)	confirmed	a	significant	main	effect	of	Trial	(F(15,120)	=	
2.490,	p	=	.003)	reflecting	the	fact	that	both	groups	exhibited	longer	run	times	as	
testing	continued.	Despite	the	apparent	differences	between	the	lesioned	and	non-
lesioned	groups,	there	was	no	main	effect	of	Group	(F(1,8)=1.139,	p	=	.317),	nor	a	
statistically	significant	Group	x	Trial	interaction	(F(15,120)=.996,	p	=	.464).		
	 The	data	analyses	for	approach-avoidance	retreat	behavior	produced	results	
comparable	to	those	obtained	for	run	time	(Figure	5.1,	Bottom	panel)	in	that	there	
was	a	significant	main	effect	of	Trials	(F(15,120)=2.838,	p	=	.001),	but	no	main	effect	
of	Group	(F(1,8)=.303,	p	=	.597),	nor	a	Group	x	Trials	interaction	(F(15,120)=.995,	p	=	
.465).		
5.3.4	Locomotor	Activity	Test	
	 The	locomotor	activity	of	the	animals	was	observed	during	a	single	30-min	
test.	For	clarity,	the	two	vehicle	groups	were	combined	and	compared	to	the	LHb	
and	BNST	lesioned	groups	(Figure	5.3).		The	activity	data	(distance	traveled	during	
each	5-min	bin)	were	then	analyzed	by	a	two-factor	(Group	x	Time)	ANOVA.	As	the	
figure	clearly	depicts,	there	was	a	significant	main	effect	of	Time	(F(5,245)=96.442,	p	
<	.001),	reflecting	the	fact	that	on	average	all	animals	reduced	their	activity	as	
testing	continued	and	they	habituated	to	the	apparatus.	However,	once	again,	there	
was	no	main	effect	of	Group	(F(2,49)=1.497,	p	=	.234),	nor	a	Group	x	Time	
interaction	(F(10,245)=1.371,	p	=	.194),	demonstrating	that	the	animals’		
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Figure	5.3	Group	Mean	(±SEM)	spontaneous	locomotor	activity	of	animals	who	
received	5,7-DHT	lesions	of	either	the	LHb	or	BNST,	and	vehicle	treated	animals	(of	
both	regions).	The	total	distance	traveled	(cm)	was	recorded	over	5-min	intervals	for	
a	30-min	test	session.	No	group	differences	in	activity	were	observed.	 	
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spontaneous	locomotor	activity	was	unaffected	by	serotonergic	lesions	of	either	the	
LHb	or	BNST.	
5.4	Conclusions	
• Animals	running	the	alley	for	i.v.	cocaine	and	pre-treated	with	intracranial	
infusions	of	vehicle	behaved	as	expected	from	numerous	previous	published	
studies	as	well	as	from	the	results	observed	in	Chapters	3	and	4	–	i.e.,	these	
subjects	exhibited	decreases	in	start	latencies	and	increases	in	run	times	and	
retreat	frequencies	as	testing	progressed.			
• Unlike	the	results	of	prior	experiments	involving	intra-LHb	or	-BNST	
applications	of	the	5-HT1B	agonist,	CP	94,253,	putative	lesions	of	the	5-HT	
terminals	in	these	two	target	areas	did	not	reliably	alter	the	runway	behavior	
of	animals	working	for	cocaine,	nor	did	the	application	of	the	5-HT	
neurotoxin	5,7-DHT	affect	the	animals’	spontaneous	locomotor	activity.	
• At	face	value,	the	failure	to	obtain	statistically	significant	results	with	the	two	
lesions	experiments	described	above	challenges	the	hypothesis	that	5-HT	
release	within	the	LHb	and	BNST	is	contributing	to	the	anxiogenic	response	
to	cocaine,	since	elimination	of	the	5-HT	terminals	ought	to	have	produced	
effects	comparable	to	a	reduction	in	5-HT	release	presumed	to	have	
occurred	with	infusions	of	CP	94,253.		Unfortunately,	any	firm	conclusions	
are	impossible	to	draw	due	to	difficulties	that	arose	with	the	histological	
confirmation	of	lesion	efficacy.	The	problems	stemmed	from	the	use	of	
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antibodies	employed	for	visualizing	5-HT	(Rabbit	anti-5-HT,	Immunostar)	
itself	as	well	as	SERT	(Rabbit	anti-SERT,	Immunostar),	the	serotonin	
transporter,	both	of	which	failed	to	produce	confirmation	of	5-HT	neurons	in	
non-lesioned	controls.		Hence,	there	was	no	way	to	determine	whether	or	
not	the	application	of	5,7-DHT	produced	the	selective	5-HT	lesions	that	were	
intended.	
• If,	in	fact,	5,7-DHT	infusions	did	produce	the	intended	5-HT	lesions,	and	the	
runway	behavior	was	unaltered	by	this	treatment,	then	what	explanation(s)	
can	one	provide	for	the	differential	effects	of	the	lesion	studies	and	those	
observed	using	the	5-HT1B	agonist,	CP	94,253?	While	necessarily	speculative	
in	nature,	a	discussion	of	this	possibility	is	provided	in	the	Discussion	chapter	
that	follows.	
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As	detailed	in	Chapter	1,	cocaine	has	been	shown	to	produce	dual	rewarding	
and	aversive	effects	in	both	humans	and	other	animals	(Anthony	et	al.,	1989;	Costall	
et	al.,	1989;	Ettenberg	et	al.,	1999;	Resnick	et	al.,	1977;	Rogerio	&	Takahashi,	1992;	
Williamson	et	al.,	1997).	These	dual	and	opposing	positive/negative	effects	of	
cocaine	fit	well	with	Solomon	&	Corbitt’s	(1974)	“opponent-process	theory”,	which	
states	that	any	affective	stimulus	(whether	positive	or	negative)	will	trigger	the	
activation	of	an	opponent	process	whose	function	is	to	return	the	organism	back	to	
affective	homeostasis.		The	experimental	results	presented	within	this	thesis	support	
this	theory	and	further	extend	the	body	of	knowledge	in	two	key	areas:	1)	it	builds	
upon	previous	research	from	our	laboratory	that	investigated	the	role	of	NE	and	CRF	
signaling	in	the	BNST	(Ettenberg,	Cotten,	Brito,	Klein,	Ohana,	Margolin,	Wei,	&	
Wenzel,	2015;	Wenzel	et	al.,	2014,	2011)	and	DA	signaling	within	the	LHb	(Shelton	et	
al.,	2016),	as	well	as	experiments	that	have	shown	a	more	global	role	of	5-HT	in	
modulating	these	dual	effects	of	cocaine	(Ettenberg	&	Bernardi,	2006,	2007;	
Ettenberg,	Ofer,	Mueller,	Waldroup,	Cohen,	&	Ben-Shahar,	2011),	and	2)	this	thesis	
identifies	a	potential	neurochemical	mechanism	for	how	5-HT	signaling	in	these	two	
brain	regions	(the	BNST	and	LHb)	contributes	to	the	negative/anxiogenic	effects	of	
cocaine.	
The	bed	nucleus	of	the	stria	terminalis	(BNST)	
The	experiments	described	in	Chapter	3	explored	the	role	of	5-HT	signaling	
within	the	BNST	in	modulating	the	dual	and	opposing	consequences	of	the	drug.	To	
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accomplish	this	goal,	the	impact	of	5-HT1B	activation	was	examined	on	the	behavior	
of	animals	running	a	straight	alley	for	a	“reward”	of	i.v.	cocaine	delivered	upon	goal-
box	entry.	These	results	confirm	previous	findings	showing	that	cocaine-reinforced	
animals	develop	a	characteristic	pattern	of	retreat	behaviors,	reflecting	an	
approach/avoidance	conflict	about	entering	a	goal	box	with	which	the	subject	has	
formed	mixed	positive	and	negative	associations	(see	Ettenberg	et	al	1999;	
Ettenberg	2004;	Raven	et	al	2000;	Jhou	et	al	2013).	Pretreating	animals	with	a	
selective	5-HT1B	agonist	delivered	into	the	BNST	significantly	decreased	expression	
of	retreat	behaviors,	a	result	consistent	with	the	hypothesis	that	serotonergic	
release	within	the	BNST	contributes	to	and/or	modulates	the	aversive/anxiogenic	
response	to	cocaine.	This	conclusion	is	further	strengthened	by	the	fact	that	
treatment	with	the	autoreceptor	agonist	did	not	have	a	significant	effect	on	the	
animals’	spontaneous	locomotor	activity,	indicating	that	the	reduction	in	runway	
retreat	behaviors	was	not	due	to	a	nonspecific	sedative	effect	of	the	treatment.			
Of	course,	reductions	in	approach-avoidance	conflict	(retreats)	could	
conceivably	occur	in	response	to	a	treatment-induced	enhancement	in	the	
rewarding	properties	of	cocaine	(as	opposed	to	a	reduction	in	the	negative	actions	
of	the	drug).	Indeed,	previous	studies	on	the	role	of	5-HT1B	receptors	in	drug	
addiction	have	demonstrated	an	involvement	of	this	receptor	in	increasing	the	
reward	value	of	cocaine	(Parsons	et	al	1998;	Filip	et	al	2010)	and	amphetamines	
(Miszkiel	et	al	2011).	More	specifically,	Filip	and	colleagues	(2010),	showed	that	
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intra-VTA	injections	of	a	5-HT1B	antagonist	impaired	cocaine	discrimination	in	a	
dose-dependent	manner,	while	application	of	a	5-HT1B	agonist	enhanced	
discrimination	of	lower	doses	of	cocaine.	The	agonist	alone	also	showed	partial	
substitution	for	cocaine,	suggesting	an	involvement	of	these	receptors	in	the	
subjective	effects	of	cocaine.	In	the	study	by	Parsons	et	al	(1998),	both	systemic	and	
intra-ventricular	treatment	with	multiple	different	5-HT1B	agonists	produced	operant	
behaviors	that	mirror	what	is	seen	when	increasing	the	unit	dose	of	cocaine	under	
both	a	fixed-ratio	and	progressive-ratio	schedule	of	reinforcement,	suggesting	5-
HT1B	activation	produces	an	increase	in	the	reward	value	of	cocaine.	Additionally,	
viral	vector-mediated	overexpression	of	5-HT1B	receptors	in	the	efferent	projections	
from	the	nucleus	accumbens	to	the	VTA,	enhanced	locomotor	sensitization	as	well	
as	strengthened	the	development	of	conditioned	place	preferences	to	low	doses	of	
cocaine	(Neumaier	et	al	2002).	In	a	study	of	5-HT1B	knockout	mice,	these	animals	
showed	an	enhanced	response	to	cocaine,	as	well	as	increases	in	cocaine	self-
administration,	which	lead	the	authors	to	propose	5-HT1B-knockout	mice	as	a	model	
of	vulnerability	to	cocaine	addiction	(Castanon,	Scearce-Levie,	Lucas,	Rocha,	&	Hen,	
2000).	So	perhaps	5-HT1B	applications	produced	an	increase	in	reward	and	not	a	
decrease	in	cocaine-induced	anxiety.	
However,	in	the	experiments	described	in	Chapters	3	(and	4),	while	the	
animals’	start	latencies	(the	time	it	took	for	subjects	to	initiate	responding	by	leaving	
the	start	box)	of	animals	significantly	decreased	over	trials	(suggesting	that	the	
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motivation	to	seek	the	drug	increased	as	testing	progressed),	there	was	no	
difference	in	this	effect	between	groups.	Thus,	there	was	no	evidence	that	the	goal	
box	experience	was	more	rewarding	(and	hence	more	motivating)	in	the	groups	
pretreated	with	of	CP	94,253	than	in	the	vehicle	control	group.	Indeed,	the	fact	that	
the	animals’	start	latencies	were	unaltered	by	the	infusion	of	CP	94,253	into	the	
BNST	(or	LHb),	suggests	that	the	motivation	to	seek	the	cocaine	was	unaffected,	
while	the	reduction	in	retreats	suggests	that	the	negative	consequences	of	cocaine	
were	reduced.		Of	course,	a	selective	decrease	in	the	negative	properties	of	cocaine	
would	nevertheless	predict	a	more	positive	experience	for	the	subject.	It	therefore	
seems	reasonable	to	suggest	that	the	enhanced	cocaine-reward	effects	observed	by	
others	following	administration	of	5-HT1B	agonists	into	the	VTA	might	similarly	be	
due	to	a	reduction	in	the	negative/anxiogenic	effects	of	the	cocaine	as	opposed	to	a	
direct	action	on	reward	circuitry.		
Another	explanation	for	the	differences	in	the	conclusions	drawn	in	the	
current	thesis	and	those	of	the	previous	studies	described	above,	is	the	reasonable	
possibility	that	serotonergic	actions	in	such	distinct	brain	regions	as	the	BNST,	LHb	
and	VTA	are	involved	in	different	aspects	of	the	response	to	cocaine.	For	example,	it	
has	been	suggested	that	activation	of	5-HT1B	receptors	on	GABAergic	neurons	of	the	
VTA	could	lead	to	a	disinhibition	of	dopamine	release	through	a	reduction	in	the	
tonic	GABA	activity	within	this	region	(Castanon	et	al	2000;	Filip	et	al	2003).		This	
would	allow	for	a	5-HT1B	mediated	potentiation	of	cocaine’s	rewarding	effects.	
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Therefore,	application	of	a	5-HT1B	agonist	to	the	VTA	may	indeed	increase	cocaine	
reward	through	the	interaction	with	dopamine,	while	the	same	drug	acting	in	the	
BNST	(or	LHb)	could	enhance	the	net	reward	value	via	a	reduction	in	the	
anxiogenic/negative	actions	of	cocaine.		
It	is	also	worth	noting	that,	with	respect	to	the	BNST,	there	is	evidence	of	a	
direct	neuronal	connection	between	it	and	the	VTA	(Jennings	et	al	2013;	Sparta	et	al	
2013;	Adhikari	2014;	Stamatakis	et	al	2014).	This	projection	from	the	BNST	appears	
to	have	a	prominent	role	in	regulation	of	VTA	dopaminergic	cells	(Jalabert	et	al	
2009).	These	projections	originate	from	the	ventral	BNST	and	have	a	strong	
excitatory	connection	to	the	VTA	(Aston-Jones	et	al.	2001;	Georges	and	Aston-Jones	
2002).	The	role	of	VTA	dopamine	in	reward	related	behaviors,	including	cocaine	
reinforcement,	has	been	well	documented	(e.g.,	McBride	et	al.	1999;	Koob	2003;	
Stuber	et	al.	2012;	George	et	al.	2012;	Jennings	et	al.	2013;	Koob	and	Volkow	2016).	
Thus,	it	seems	likely	that	the	BNST	can	modulate	the	affective	response	to	cocaine	
through	this	pathway.	However,	because	this	excitatory	vBNST	->	VTA	projection	is	
necessary	for	cocaine	preference	(Sartor	and	Aston-Jones	2012),	and	activation	of	
the	5-HT1B	receptor	produces	presynaptic	inhibition	of	glutamatergic	and	
serotonergic	inputs	(Hammack	et	al.,	2009),	one	would	then	expect	the	present	
manipulation	to	reduce	activity	in	the	vBNST	->	VTA	pathway	leading	to	a	reduction	
in	the	reinforcing	properties	in	cocaine.	This	effect	was	not	observed	(i.e.,	start	
latencies	continued	to	improve	over	trials),	thus	leading	to	the	conclusion	that	the	
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activation	of	5-HT1B	receptors	in	the	overall	BNST	leads	to	a	reduction	in	the	
anxiogenic	effects	of	cocaine	without	increasing	the	rewarding	effects.	The	
microinjection	methods	employed	in	this	study	are	not	precise	enough	to	accurately	
target	specific	subregions	of	the	BNST.	Nevertheless,	as	5-HT	is	a	diffuse	modulatory	
neurotransmitter,	the	present	aim	was	simply	to	investigate	the	effect	of	reducing	
overall	5-HT	signaling	in	this	region	via	targeting	the	presynaptic	autoreceptors.	
Therefore,	it	is	not	possible	from	this	investigation	to	make	any	claims	about	
subregion	specific	effects	of	the	manipulation.	
Experiment	II	was	conducted	to	obtain	further	insight	into	the	behavioral	
mechanism	by	which	intra-BNST	administration	of	CP	94,253	reduced	the	animal’s	
approach-avoidance	conflict	in	the	runway.	Since	pretreatment	with	drugs	like	
diazepam	have	also	been	shown	to	reduce	approach-avoidance	retreats	(Ettenberg	
and	Geist	1991),	it	is	possible	that	the	5-HT1B	agonist	pretreatment	(Experiment	I)	
was	acting	as	a	general	anxiolytic	that	reduced	retreats	not	by	interfering	with	the	
delayed	negative	consequences	of	cocaine,	but	more	simply	by	reducing	the	
animals’	general	anxiety	prior	to	each	trial.	This	seems	plausible	given	that	
experiments	with	systemic	administration	of	5-HT1B	agonists	have	demonstrated	
anxiolytic	and	antidepressant-like	effects	(Tatarczyńska	et	al.	2004;	2005).	It	was	
therefore	of	interest	to	determine	whether	BNST	application	of	CP	94,253	after	the	
runway	trial	but	before	the	onset	of	cocaine’s	negative	effects	(which	have	been	
shown	to	reach	peak	levels	in	rats	15-min	post	iv	injection;	see	Ettenberg	et	al	1999;	
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Knackstedt	et	al	2002;	Jhou	et	al	2013)	would	similarly	reduce	approach-avoidance	
retreat	behaviors	in	the	runway.		The	observed	reduction	in	runway	retreat	
behaviors	produced	by	this	treatment	could	not,	therefore,	be	easily	accounted	for	
by	any	indirect	or	nonspecific	action	of	the	treatment	on	either	the	animals’	anxiety	
prior	to	the	start	of	testing	nor	their	behavioral	capacity	since	the	subjects	were	
running	prior	to	the	delivery	of	either	the	cocaine	or	the	CP	94,253.			
Although	there	were	modest	differences	in	the	number	of	retreats	
performed	by	the	vehicle	groups	between	Experiments	I	and	II,	this	was	not	
unexpected	given	the	inherent	response	variability	observed	in	numerous	previous	
experiments	using	the	runway.	Because	animals	in	Experiment	II	went	directly	from	
their	home	cage	to	the	runway,	it	is	possible	that	they	experienced	heightened	
anxiety	at	the	onset	of	the	test.	In	Experiment	I,	there	was	a	delay	between	animal’s	
removal	from	their	home	cage	and	their	placement	in	the	runway	during	which	each	
received	its	microinjection.	This	slight	difference	in	procedure	provided	animals	in	
Experiment	I	time	to	anticipate	the	runway	trial,	which	could	explain	why	they	
showed	a	lower	maximum	number	of	retreats.	In	any	event,	when	taken	together,	
the	current	results	are	consistent	with	the	conclusion	that	the	comparable	effects	of	
the	pre-	and	post-treatment	application	of	CP	94,253	were	due	to	an	alteration	of	
the	impact	of	the	delayed	negative	consequences	of	cocaine	administration.		
It	is	also	interesting	to	note	that	the	vast	majority	of	literature	investigating	
the	role	of	the	BNST	in	mediating	the	aversive	effects	of	drugs	like	cocaine	has	been	
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focused	on	drug	withdrawal	(George,	Le	Moal,	&	Koob,	2012;	Jalabert,	Aston-Jones,	
Herzog,	Manzoni,	&	Georges,	2009;	Koob,	2003,	2008).	Indeed,	the	extended	
amygdala	appears	to	be	a	major	part	of	the	brain	circuitry	that	mediates	stress-
induced	relapse	to	drugs	of	abuse	(Erb,	2010;	Ventura-Silva	et	al.,	2012).	However,	
the	studies	described	in	this	thesis	highlight	a	role	for	the	BNST	in	modulating	the	
negative	effects	of	cocaine	after	acute	administration,	and	not	just	after	withdrawal	
from	chronic	drug	exposure.	This	finding	is	consistent	with	previous	work	from	our	
laboratory	which	similarly	showed	a	role	for	the	BNST	itself	(Wenzel	et	al.,	2011),	as	
well	as	NE	signaling	within	this	region	(Wenzel	et	al.,	2014)	in	mediating	the	acute	
negative	effects	of	cocaine.	Taken	together,	these	findings	show	that	the	BNST	is	not	
only	responsible	for	the	negative	effects	of	cocaine	withdrawal,	but	that	it	plays	a	
role	in	the	acute	negative	effects	of	the	drug	as	well.	
	 Finally,	it	is	fully	acknowledged	that	the	current	interpretation	of	these	
findings	is	suggestive	rather	than	conclusive	and	that	the	precise	mechanism(s)	
through	which	5-HT	is	acting	in	the	BNST	to	alter	the	behavioral	response	to	cocaine	
remain(s)	to	be	elucidated.	For	example,	it	has	been	established	that	5-HT1B	
receptors	are	not	exclusively	located	on	5-HT	pre-synaptic	elements	--	they	also	exist	
as	heteroreceptors	on	the	terminals	of	glutamatergic	neurons	that	synapse	within	
the	BNST	(Guo	and	Rainnie	2010).	Thus,	while	there	is	evidence	that	the	5-HT1B	
receptor	exists	primarily	on	the	presynaptic	membrane	in	regions	receiving	5-HT	
projections	(Riad	et	al.	2000),	it	nevertheless	remains	to	be	determined	whether	the	
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reductions	in	retreat	behavior	observed	in	the	present	study	are	due	to	CP	94,253’s	
putative	inhibitory	effects	on	5-HT	release,	or	to	an	impaired	functioning	of	a	
glutamatergic	excitatory	“driver”	input.	That	being	stated,	5-HT1B	hetereoreceptors	
do	show	a	lower	sensitivity	to	5-HT1B	agonists	than	5-HT1B	autoreceptors	(Sarhan	
and	Fillion	1999).	Consequently,	it	may	be	that	the	non-dose	dependent	effect	on	
retreat	behavior	observed	in	the	present	study	was	due	to	the	loss	of	specificity	to	
serotonergic	autoreceptors.	The	fact	that	a	typical	dose-response	curve	was	not	
observed	suggests	that	the	doses	used	in	this	study	likely	fall	on	the	upper	end	of	
the	dose	range	for	this	drug.		
The	Lateral	Habenula	(LHb)	
The	experiments	described	in	Chapter	4	examined	the	impact	of	5-HT1B	
receptor	stimulation	in	the	LHb	on	the	behavior	of	animals	running	a	straight	alley	
for	i.v.	cocaine	reinforcement.	Much	as	it	did	in	the	BNST	(Chapter	3),	application	of	
a	selective	5-HT1B	agonist	into	the	LHb	produced	no	effects	on	start	latency,	an	
increase	in	run	times,	and	a	corresponding	dose-dependent	decrease	in	the	
frequency	of	runway	retreat	behaviors,	an	effect	that	was	reversed	by	co-
administration	with	a	selective	5-HT1B	antagonist.		
Once	again,	these	results	cannot	be	easily	accounted	for	by	some	form	of	
nonspecific	motoric	effects	of	the	treatment,	since	neither	treatment	protocol	
produced	alterations	in	the	spontaneous	locomotor	activity	of	subjects.	Additionally,	
and	as	discussed	above	for	the	BNST,	while	one	might	argue	that	the	observed	
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reductions	in	retreat	behavior	reflect	an	increase	in	the	rewarding	properties	of	
cocaine,	to	turn	the	argument	on	its	head,	a	presumed	enhancement	in	cocaine	
reward	after	intraventricular	administration	of	a	5-HT1B	agonist,	as	suggested	by	
Parsons	et	al.	(1998)	could	in	fact	have	been	due	to	a	reduction	in	the	drug’s	
aversive	effects,	leading	to	a	net	increase	in	reward.	Indeed,	when	a	5-HT1B	agonist	is	
administered	systemically,	it	would	be	difficult	to	tease	apart	potentially	opposing	
actions	stemming	from	drug	effects	in	different	brain	regions.	Finally,	in	the	current	
set	of	LHb	experiments,	as	was	the	case	in	Chapter	3	for	the	BNST	experiments,	CP	
94,253	produced	no	enhancement	of	start	latencies,	which	would	have	been	
expected	if	cocaine-reward	had	been	increased.	Thus,	when	taken	together,	the	
current	findings	are	consistent	with	the	hypothesis	that	the	observed	reductions	in	
approach-avoidance	retreat	behaviors	were	due,	not	to	an	elevation	in	the	
rewarding	properties	of	cocaine,	but	rather	to	a	reduction	in	the	drug’s	
negative/anxiogenic	effects.	
	 But	what	is	the	neurobiological	basis	for	the	behavioral	effects	of	intra-LHb	
CP	94,253	in	cocaine-reinforced	animals?	There	is	ample	evidence	demonstrating	an	
intimate	inverse	relationship	between	the	VTA	and	LHb.	Early	studies	investigating	
this	relationship	found	that	stimulation	of	the	LHb	produces	an	inhibition	of	VTA	DA	
cell	firing	(Christoph	et	al.,	1986).	It	was	later	shown	by	Matsumoto	&	Hikosaka	
(2007)	that	this	circuit	is	responsible	for	encoding	an	“anti-reward”	signal.	Their	
experiments	elegantly	showed	how	the	LHb	responds	to	both	negative	outcomes,	as	
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well	as	the	lack	of	an	expected	reward,	by	an	increase	in	its	own	activity	while	
simultaneously	inhibiting	the	VTA.	Likewise,	the	rewarding	conditions	that	produced	
strong	activations	of	VTA	DA	cells	also	inhibited	the	activity	of	LHb	neurons	
(Matsumoto	&	Hikosaka,	2007).	In	later	research,	as	described	in	Chapter	1,	these	
projections	from	the	LHb	were	found	to	be	glutamatergic	and	inhibitory	to	the	VTA	
via	activation	of	GABAergic	cells	of	the	RMTg	–	a	region	immediately	adjacent	to	the	
VTA	(Jhou,	Fields,	et	al.,	2009;	Stamatakis	&	Stuber,	2012).	Additionally,	the	reverse	
pathway	has	also	been	identified	using	optogenetic	methods—a	population	of	
presumptively	GABAergic	VTA	neurons	that	inhibit	the	LHb	and	promote	reward	
(Stamatakis	et	al.,	2013).	Jhou	et	al.	(2013)	have	also	reported	that	the	initial	
rewarding	effects	of	cocaine	are	associated	with	an	inhibition	of	LHb	neurons	and	
that	the	onset	of	the	delayed	anxiogenic	response	to	the	drug	is	directly	associated	
with	an	increase	in	LHb	activity	and	a	resulting	suppression	of	VTA	DA	neurons.	
When	viewed	in	this	context,	the	current	findings	might	suggest	a	role	for	5-HT	
release	within	the	LHb	as	a	contributing	factor	to	the	LHb’s	modulation	of	the	
affective	response	to	cocaine.		
	 In	addition	to	its	role	in	regulating	the	VTA,	the	LHb	is	also	one	of	the	major	
inputs	to	the	dorsal	and	median	raphé	5-HT	systems	(see	Metzger,	Bueno,	&	Lima,	
2017	for	a	recent	review).	While	the	LHb	has	been	shown	to	receive	reciprocal	
projections	back	from	the	DRN	(Zhao,	Zhang,	Yang,	&	Rusak,	2015),	the	bulk	of	5-HT	
innervation	targets	the	medial	habenula	(MHb)	(Metzger	et	al.,	2017;	Morin	&	
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Meyer-Bernstein,	1999;	Tchenio	et	al.,	2016;	Wagner,	Bernard,	et	al.,	2016;	Wagner,	
French,	et	al.,	2016).	Analysis	of	mRNA	transcripts	in	this	region	suggests	that	the	5-
HT1B	receptor	has	an	elevated	expression	in	the	LHb	versus	the	MHb	(Metzger	et	al.,	
2017;	Wagner,	Bernard,	et	al.,	2016;	Wagner,	French,	et	al.,	2016),	which	again	
support	the	hypothesis	that	the	observed	behavioral	effects	described	in	Chapter	4	
were	due	primarily	to	modulation	of	the	LHb,	rather	than	MHb.		However,	due	to	
the	relatively	small	size	and	immediate	adjacency	of	the	LHb	and	MHb,	it	cannot	be	
conclusively	determined	with	any	anatomical	precision	whether	our	manipulations	
produced	their	effects	via	modulation	of	the	LHb,	MHb,	or	both	structures.		
Although	most	of	the	research	in	this	area	has	focused	on	the	LHb,	the	MHb	
has	also	been	implicated	in	modulating	the	same	affective	states	as	the	LHb,	
including	drug	withdrawal,	depression,	stress,	and	anxiety	(Viswanath,	Carter,	
Baldwin,	Molfese,	&	Salas,	2014).	The	MHb	has	also	received	a	renewed	interest	for	
its	role	in	nicotine	addiction,	due	to	the	discovery	that	it	contains	a	high	
concentration	of	nicotinic	ACh	receptors	and	has	outputs	to	areas	that	regulate	ACh	
release	throughout	the	brain	(Viswanath	et	al.,	2014).	Clearly	there	is	a	need	for	
more	research	on	the	MHb	and	its	role	in	the	behavioral	effects	of	drugs	of	abuse.	
The	effects	of	selective	lesions	of	5-HT	terminals	in	the	LHb	and	BNST	
	 Serotonin	appears	to	have	mixed	effects	in	the	LHb.	On	post-synaptic	LHb	
neurons,	5-HT	produces	primarily	stimulatory	effects	via	activation	of	5-HT2/3	
receptors,	which	enhance	cellular	depolarization	(L.-N.	Han,	Zhang,	Li,	Sun,	Wang,	
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Chen,	Guo,	Zhang,	Zhang,	&	Liu,	2015;	Zuo,	Zhang,	Xie,	Gregor,	Bekker,	&	Ye,	2016).	
5-HT	can	also	act	as	an	inhibitory	signal	through	activation	of	inhibitory	5-HT1B	
heteroreceptors	located	presynaptically	on	the	glutamatergic	inputs	to	the	LHb	
(Hwang	&	Chung,	2014;	Xie,	Zuo,	Wu,	Li,	Wu,	Bekker,	&	Ye,	2016).	Additionally,	local	
application	of	a	5-HT1B	agonist	into	the	LHb	has	been	shown	to	reduce	5-HT	release	
as	measured	through	microdialysis	(Adell	et	al.,	2001).	Thus,	there	are	two	possible	
mechanisms	that	could	explain	the	results	observed	in	the	current	set	of	LHb	
experiments.	First,	it	could	be	that	the	5-HT1B	agonist	is	reducing	LHb	activity	
indirectly	via	inhibition	of	glutamatergic	inputs	to	the	LHb;	alternatively,	these	
results	could	be	explained	by	an	inhibition	of	5-HT	release	in	the	LHb	via	activation	
of	the	5-HT1B	autoreceptors	localized	on	the	serotonergic	fibers	innervating	this	
region.	The	experiments	described	in	Chapter	5	attempted	to	distinguish	between	
these	two	possibilities	using	selective	neurotoxic	lesions.	
	 Unfortunately,	as	described	above,	the	lesion	experiments	suffered	from	two	
major	(but	related)	issues:	1)	the	inability	to	verify	through	immunohistochemistry	
the	extent	and	effectiveness	of	5,7-DHT	lesions,	and	2)	the	small	sample	size	in	the	
BNST	experiment	(which	was	a	consequence	of	our	decision	to	stop	testing	animals	
due	to	the	unreliability	of	the	antibodies	we	employed	for	visualizing	5-HT	and	
SERT).	Ultimately,	these	issues	resulted	in	an	inability	to	verify	whether	or	not	the	
neurotoxic	treatments	had	in	fact	produced	viable	5-HT	lesions.		Part	of	the	problem	
is	the	paucity	of	serotonergic	fibers	in	this	region.	However,	we	did	also	look	for	5-
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HT-positive	fibers	in	other	nearby	regions	(e.g.,	MHb,	striatum,	and	cerebral	cortex)	
and	failed	to	find	them,	which	lead	to	the	conclusion	that	the	IHC	staining	did	not	
work.	
By	way	of	speculation	–	if	in	fact	the	lesions	successfully	destroyed	the	5-HT	
terminals	(as	we	had	planned	but	were	unable	to	confirm),	and	this	produced	no	
change	in	the	anxiogenic	response	to	cocaine,	then	the	results	observed	in	Chapters	
3	and	4	may	conceivably	have	been	due	to	modulation	of	glutamatergic,	rather	than	
serotonergic,	inputs	to	the	LHb.	As	described	in	Chapter	1,	the	effects	of	5-HT	in	the	
LHb	are	complex,	showing	both	inhibition	and	excitation	(Han	et	al.,	2015;	Zuo	et	al.,	
2016).	If	the	putative	5,7-DHT	lesion	and	the	administration	of	a	5-HT1B	agonist	(in	
Chapter	4)	produced	different	effects	on	retreat	behavior,	it	is	reasonable	to	
conclude	that	the	5-HT1B	agonist	effects	might	have	resulted	from	an	inhibition	of	
the	glutamatergic	drive	onto	the	LHb,	and	not	from	a	reduction	in	5-HT	release,	as	
originally	proposed.	Thus,	assuming	the	lesions	were	successful,	this	would	imply	
that	the	role	of	5-HT	within	the	LHb	is	modulatory	in	nature,	and	not	critical	for	the	
development	of	approach-avoidance	retreat	behavior.	
The	explanation	for	the	failure	of	the	5-HT	lesions	in	the	BNST	(Chapter	3)	is	
even	more	inconclusive	due	to	the	high	within-group	variability,	the	small	sample	
sizes,	and	the	inability	to	verify	the	efficacy	of	the	lesion.	Experiment	VII	was	being	
conducted	at	the	same	time	as	the	histology	from	Experiment	VI.	When	the	problem	
of	visualizing	the	lesions	was	encountered,	the	decision	was	made	to	not	add	further	
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animals	to	increase	group	sizes,	since	it	was	clear	from	the	LHb	lesion	experiment	
that	we	would	be	unable	to	be	histologically	verify	the	lesion.		By	this	point,	the	5,7-
DHT	lesion	experiments	had	already	represented	a	year	and	a	half	of	work.	Thus,	the	
decision	was	made	to	cease	this	line	of	enquiry.		
To	conclude,	while	the	lesion	experiments	leave	some	questions	
unanswered,	the	work	described	in	this	dissertation	makes	a	number	of	valuable	
contributions	towards	developing	a	better	understanding	of	the	aversive	effects	of	
cocaine.	First,	it	demonstrates	the	importance	of	serotonin	signaling	in	both	the	
BNST	and	LHb,	two	regions	that	have	been	associated	with	anxiety	and	aversion.	The	
CP	94,253	experiments	described	in	this	dissertation	join	fewer	than	a	half-dozen	
published	reports	on	the	intracranial	administration	of	this	compound.	Additionally,	
the	studies	described	in	this	dissertation	are	the	first,	and	only,	published	
experiments	that	use	NAS-181	intracranial	infusions	to	block	the	behavioral	effects	
of	a	co-administered	5-HT1B	agonist.	The	dissertation,	therefore,	adds	to	a	growing	
body	of	literature	about	the	relationship	between	serotonin	and	the	aversive	effects	
of	cocaine.	Taken	together,	the	experiments	described	herein	provide	further	
evidence	in	support	of	Solomon	&	Corbit’s	(1974)	opponent	process	theory	of	
motivated	behavior,	as	it	relates	to	cocaine.	With	selective	modulation	of	5-HT	
activity	in	the	BNST	and	LHb,	it	is	possible	to	partially	negate	the	aversive	“B”	
process,	demonstrating	that	the	“A”	and	“B”	processes	are	indeed	dissociable	and	
arise	from	distinct	neuroanatomical	networks	in	the	brain.	
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Limitations	and	Caveats	
	 One	major	caveat	of	this	research	is	the	fact	that	5-HT	release	was	never	
measured	directly	in	any	experiment.	Therefore,	it	is	impossible	to	say	with	any	
certainty	whether	the	5-HT1B	manipulations	(in	Chapters	3	&	4)	actually	caused	a	
decrease	in	5-HT	release.	However,	microdialysis	experiments	have	shown	the	
efficacy	of	5-HT1B	selective	agonists	at	reducing	5-HT	release	within	the	LHb	(Adell	et	
al.,	2001).	Similar	work	has	also	shown	that	the	5-HT1B	antagonist	used	in	this	work,	
NAS-181,	can	block	5-HT1B	mediated	suppression	of	5-HT	release	(De	Groote	et	al.,	
2003).	Although	these	studies	provide	evidence	for	a	5-HT1B	mediated	reduction	in	
5-HT	release,	the	research	presented	in	this	thesis	does	not	include	any	direct	
measurements	of	5-HT.		
	 A	second	major	caveat	of	this	thesis	is	that	there	were	no	direct	observations	
of	5-HT1B	receptor	activity	or	expression	made	in	any	experiments.	The	drugs	used	to	
manipulate	5-HT1B	activity	were	given	daily,	for	17	consecutive	days,	in	each	
experiment.	This	dosing	regimen	may	have	been	sufficient	to	induce	tolerance	to	the	
treatment	over	the	course	of	testing.	The	treatment	may	have	caused	compensatory	
responses	in	receptor	expression,	agonist	binding,	or	recruitment	of	downstream	
signaling	cascades.	Additionally,	it	is	unknown	how	daily	infusions	of	cocaine	may	
affect	this	receptor.		
	 Additionally,	there	is	evidence	that	5-HT1B	heteroreceptors	can	also	regulate	
the	release	of	other	neurotransmitters,	including	GABA	(Hashimoto	&	Kita,	2008;	
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Peruzzi	&	Dut,	2004).	So,	in	addition	to	regulation	of	glutamate	and	5-HT,	the	5-HT1B	
receptor	also	regulates	inhibitory	transmission	throughout	the	brain.	Thus,	it	is	
possible	that	manipulations	targeted	at	this	receptor	produce	off	target	effects	on	
GABA	terminal	as	well.	
	 The	5-HT1B	receptor	is	also	constitutively	active,	a	feature	that	is	critical	for	
the	axonal	targeting	and	subcellular	localization	of	this	receptor	(Carrel,	Simon,	
Emerit,	Rivals,	Leterrier,	Biard,	Hamon,	Darmon,	&	Lenkei,	2011).	Because	this	
receptor’s	subcellular	localization	is	dependent	upon	the	its	activity,	it	is	possible	
that	daily	infusions	of	a	5-HT1B	agonist	could	produces	alterations	in	receptor	
localization	or	expression.	
	 Finally,	the	studies	that	utilized	5,7-DHT	lesions	of	the	serotonergic	fibers	are	
also	subject	to	an	important	caveat:	lesioned	fibers	would	also	disrupt	signaling	
through	any	fibers	of	passage,	causing	potential	off-target	effects	in	regions	far	from	
the	targeted	site.	Because	5-HT	is	a	diffuse	modulatory	system	that	releases	
neurotransmitter	through	a	meshwork	of	varicosities,	rather	than	point-to-point	
synaptic	transmission,	even	a	localized	lesion	could	destroy	fibers	innervate	distant	
regions.	In	addition,	it	is	also	not	known	what	compensatory	changes	might	occur	in	
response	to	destruction	of	5-HT	fibers.	It	may	be	possible	that	the	lack	of	results	
seen	in	the	lesion	experiments	of	Chapter	V	could	be	due	to	a	compensatory	
response	of	other	neurotransmitter	systems	attempting	to	“fill	in	the	gaps”	caused	
by	the	loss	of	5-HT.		
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Clinical	Implications	
	 This	work	has	potential	clinical	implications,	particularly	for	the	treatment	of	
cocaine	use	disorders.	The	5-HT1B	receptor	represents	a	potential	target	for	the	
alleviation	of	cocaine’s	negative	effects.	Unlike	for	opioid	drugs	of	abuse,	there	is	
currently	no	pharmacotherapy	for	cocaine	use	disorder.	As	shown	by	the	work	in	
this	thesis,	agonists	at	the	5-HT1B	receptor	are	effective	at	reducing	the	anxiogenic	
properties	of	cocaine.	For	humans,	this	is	a	potential	avenue	for	treating	relapse.	By	
finding	a	pharmacotherapeutic	drug	that	alleviates	cocaine’s	negative	effects,	it	may	
be	possible	to	prevent	a	person	from	relapsing.	According	to	the	Koob	model	of	
addiction,	the	process	of	addiction	is	characterized	by	cycles	of	binges	and	
withdrawal,	with	the	aversive	effects	of	withdrawal	driving	the	next	drug	binge	
(Koob	&	Le	Moal,	2008).		
	 A	recent	review	article	highlights	the	potential	of	the	5-HT1B	receptor	as	a	
target	for	various	psychiatric	disorders,	including	anxiety,	depression	and	substance	
abuse	(Tiger,	Varnäs,	Okubo,	&	Lundberg,	2018).	The	authors	make	the	case	for	
targeting	the	5-HT1B	receptor,	primarily	for	the	treatment	of	Major	Depression,	and	
suggest	that	the	therapeutic	benefit	seen	with	typical	selective	serotonin	reuptake	
inhibitor	(SSRI)	antidepressants	might	be	due	to	a	downregulation	of	the	5-HT1B	
receptor.	If	this	is	true,	then	selective	5-HT1B	agonists	could	show	an	improved	
efficacy	compared	to	treatment	with	the	relatively	non-selective	SSRIs.	Additionally,	
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if	this	theory	is	correct,	5-HT1B	inverse-agonists	may	be	an	entirely	new	set	of	
potential	options	for	the	treatment	of	depression.		
	 In	human	studies	of	cocaine	dependence,	there	have	been	mixed	reports	on	
the	efficacy	of	SSRIs		in	reducing	relapse	to	the	drug,	with	some	studies	showing	an	
effect	while	others	do	not	(Moeller,	Schmitz,	Steinberg,	Green,	Reist,	Lai,	Swann,	&	
Grabowski,	2007).	The	discrepancy	in	findings	could	potentially	be	due	to	slight	
differences	in	the	mechanism	of	action	of	various	SSRIs.	One	study	in	rodents	
showed	that	fluoxetine,	but	not	sertraline	or	citalopram,	could	potentiate	the	
locomotor	response	to	cocaine	(Fletcher,	Sinyard,	Salsali,	&	Baker,	2004).	However,	
an	important	caveat	is	that	SSRIs	could	increase	the	toxic	effects	of	cocaine	(O’Dell,	
George,	&	Ritz,	2000),	which	may	preclude	the	use	of	SSRIs	in	cocaine-dependent	
patients.	Thus,	it	is	clear	more	research	is	needed	to	develop	effective	tools	for	the	
treatment	of	cocaine	dependence.			
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